This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7a-5p | CSNK2A1 | -0.03 | 0.25442 | 0.29 | 0.0016 | miRNAWalker2 validate; TargetScan | -0.7 | 0.00553 | ||
2 | hsa-let-7b-5p | CSNK2A1 | -0.12 | 0.00077 | 0.29 | 0.0016 | miRNAWalker2 validate | -0.9 | 0 | ||
3 | hsa-let-7b-5p | EP300 | -0.12 | 0.00077 | 0.11 | 0.05719 | miRNAWalker2 validate | -0.36 | 0.00159 | ||
4 | hsa-let-7c-5p | CSNK2A1 | -0.13 | 0.00086 | 0.29 | 0.0016 | miRNAWalker2 validate | -0.81 | 0 | ||
5 | hsa-let-7e-5p | PPP2R1A | -0.06 | 0.0129 | 0.19 | 0.00095 | miRNAWalker2 validate | -0.69 | 7.0E-5 | ||
6 | hsa-miR-101-3p | FZD6 | -0.13 | 4.0E-5 | 0.2 | 0.17097 | miRNAWalker2 validate; MirTarget | -1.37 | 2.0E-5 | ||
7 | hsa-miR-101-3p | RAC1 | -0.13 | 4.0E-5 | 0.12 | 0.00036 | miRNAWalker2 validate; MirTarget | -0.62 | 0 | ||
8 | hsa-miR-106b-5p | CCND1 | 0.17 | 0 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -1.84 | 0 | 23087084 | Furthermore miR-106b upregulation in hepatoma cells modulated entry into the G1/S transitional phase by upregulating cyclin D1 and downregulating APC |
9 | hsa-miR-106b-5p | CCND2 | 0.17 | 0 | -0.02 | 0.79963 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.45 | 0.00359 | ||
10 | hsa-miR-10a-5p | BTRC | -0.29 | 0 | 0.12 | 0.03999 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.21 | 0.00767 | ||
11 | hsa-miR-10a-5p | CSNK2A1 | -0.29 | 0 | 0.29 | 0.0016 | miRNAWalker2 validate | -0.75 | 0 | ||
12 | hsa-miR-10a-5p | MAP3K7 | -0.29 | 0 | 0.2 | 0.01129 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.51 | 0 | ||
13 | hsa-miR-10b-5p | CSNK2A1 | -0.03 | 0.44052 | 0.29 | 0.0016 | miRNAWalker2 validate | -0.45 | 0.01698 | ||
14 | hsa-miR-122-5p | RAC1 | -0.14 | 0.00123 | 0.12 | 0.00036 | miRNAWalker2 validate; miRTarBase | -0.49 | 0 | ||
15 | hsa-miR-122-5p | RHOA | -0.14 | 0.00123 | 0.09 | 4.0E-5 | miRNAWalker2 validate; miRTarBase | -0.28 | 0 | ||
16 | hsa-miR-122-5p | TBL1XR1 | -0.14 | 0.00123 | 0.19 | 0.03766 | miRNAWalker2 validate | -0.48 | 0.00205 | ||
17 | hsa-miR-125b-5p | FRAT2 | -0.19 | 1.0E-5 | 0.03 | 0.70845 | miRNAWalker2 validate; miRNATAP | -0.49 | 0.00035 | ||
18 | hsa-miR-126-5p | MMP7 | 0 | 0.93995 | -1.4 | 3.0E-5 | miRNAWalker2 validate | -3.81 | 0.00035 | ||
19 | hsa-miR-146a-5p | ROCK1 | -0.15 | 0.00019 | -0.04 | 0.56308 | miRNAWalker2 validate; miRTarBase | -0.24 | 0.03156 | ||
20 | hsa-miR-146a-5p | SMAD4 | -0.15 | 0.00019 | -0.02 | 0.53799 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.00261 | ||
21 | hsa-miR-149-5p | EP300 | -0.01 | 0.59412 | 0.11 | 0.05719 | miRNAWalker2 validate | -0.33 | 0.03119 | ||
22 | hsa-miR-155-5p | SMAD4 | 0.04 | 0.14794 | -0.02 | 0.53799 | miRNAWalker2 validate | -0.27 | 0.00018 | ||
23 | hsa-miR-15b-5p | CCND1 | 0.17 | 0 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -1.99 | 0 | ||
24 | hsa-miR-16-5p | TP53 | 0.05 | 0.02313 | -0.01 | 0.88204 | miRNAWalker2 validate; miRTarBase | -0.65 | 0.02034 | ||
25 | hsa-miR-17-5p | CCND1 | 0.06 | 0.05778 | -0.49 | 0.00116 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -1.31 | 0.00018 | 18695042 | Mammary epithelial cell-targeted cyclin D1 expression induced miR-17-5p and miR-20a expression in vivo and cyclin D1 bound the miR-17/20 cluster promoter regulatory region |
26 | hsa-miR-17-5p | CCND2 | 0.06 | 0.05778 | -0.02 | 0.79963 | miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP | -0.49 | 0.00112 | ||
27 | hsa-miR-17-5p | PRICKLE1 | 0.06 | 0.05778 | -0.86 | 0 | miRNAWalker2 validate | -2.03 | 0 | ||
28 | hsa-miR-17-5p | SMAD3 | 0.06 | 0.05778 | 0.25 | 0.00236 | miRNAWalker2 validate | -0.46 | 0.01666 | ||
29 | hsa-miR-181a-5p | NLK | -0.02 | 0.5042 | 0.18 | 0.00757 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.44 | 0.01709 | ||
30 | hsa-miR-181a-5p | WNT3A | -0.02 | 0.5042 | -0.04 | 0.27231 | miRNAWalker2 validate | -0.38 | 0.00037 | ||
31 | hsa-miR-183-5p | CCND1 | 0.21 | 6.0E-5 | -0.49 | 0.00116 | miRNAWalker2 validate | -1.31 | 0 | ||
32 | hsa-miR-183-5p | PPP3R1 | 0.21 | 6.0E-5 | 0.02 | 0.75276 | miRNAWalker2 validate | -0.18 | 0.02923 | ||
33 | hsa-miR-184 | NFATC2 | 0.21 | 2.0E-5 | -0.21 | 0.05152 | miRNAWalker2 validate | -0.62 | 4.0E-5 | ||
34 | hsa-miR-18a-5p | DAAM2 | 0.2 | 7.0E-5 | -0.18 | 0.03531 | miRNAWalker2 validate | -0.79 | 0 | ||
35 | hsa-miR-192-5p | FZD1 | 0.01 | 0.72622 | -0.71 | 0 | miRNAWalker2 validate | -1.67 | 0 | ||
36 | hsa-miR-192-5p | FZD7 | 0.01 | 0.72622 | -0.29 | 0.05092 | miRNAWalker2 validate | -2.06 | 0 | ||
37 | hsa-miR-192-5p | PRICKLE1 | 0.01 | 0.72622 | -0.86 | 0 | miRNAWalker2 validate | -1.61 | 1.0E-5 | ||
38 | hsa-miR-192-5p | TCF7 | 0.01 | 0.72622 | 0.15 | 0.21177 | miRNAWalker2 validate; MirTarget | -0.66 | 0.01943 | ||
39 | hsa-miR-194-5p | EP300 | 0.03 | 0.38268 | 0.11 | 0.05719 | miRNAWalker2 validate | -0.41 | 0.00207 | ||
40 | hsa-miR-194-5p | RAC1 | 0.03 | 0.38268 | 0.12 | 0.00036 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.34 | 2.0E-5 | ||
41 | hsa-miR-196a-5p | CCND2 | 0.07 | 0.01124 | -0.02 | 0.79963 | miRNAWalker2 validate | -0.48 | 0.0035 | ||
42 | hsa-miR-199a-3p | MAPK9 | -0.47 | 0 | 0.12 | 0.03801 | miRNAWalker2 validate | -0.19 | 0.0002 | ||
43 | hsa-miR-19a-3p | CCND1 | 0.02 | 0.47729 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.97 | 0.00857 | 25985117 | Moreover miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression |
44 | hsa-miR-19b-3p | CCND2 | -0.02 | 0.40277 | -0.02 | 0.79963 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.39 | 0.02187 | ||
45 | hsa-miR-19b-3p | DAAM2 | -0.02 | 0.40277 | -0.18 | 0.03531 | miRNAWalker2 validate | -0.46 | 0.03964 | ||
46 | hsa-miR-19b-3p | PRKACB | -0.02 | 0.40277 | -0.14 | 0.14062 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.68 | 0.00546 | ||
47 | hsa-miR-200a-3p | TCF7L1 | -0.48 | 0 | 0.03 | 0.57819 | miRNAWalker2 validate | -0.1 | 0.04142 | ||
48 | hsa-miR-200b-3p | TCF7L1 | -0.53 | 0 | 0.03 | 0.57819 | miRNAWalker2 validate | -0.1 | 0.04374 | ||
49 | hsa-miR-206 | CCND2 | 0.03 | 0.13251 | -0.02 | 0.79963 | miRNAWalker2 validate; PITA; miRNATAP | -0.49 | 0.02842 | 23348698 | Further studies demonstrated that miR-206 could suppress GC cells proliferation at least partially through targeting the cyclinD2 CCND2 |
50 | hsa-miR-20a-5p | CCND1 | -0.02 | 0.56346 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.89 | 0.00952 | ||
51 | hsa-miR-20a-5p | CCND2 | -0.02 | 0.56346 | -0.02 | 0.79963 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.44 | 0.00293 | ||
52 | hsa-miR-21-5p | DAAM1 | 0.23 | 0.00018 | -0.1 | 0.25736 | miRNAWalker2 validate | -0.41 | 2.0E-5 | ||
53 | hsa-miR-21-5p | PRICKLE2 | 0.23 | 0.00018 | -0.71 | 2.0E-5 | miRNAWalker2 validate; MirTarget | -0.8 | 3.0E-5 | ||
54 | hsa-miR-210-3p | APC | 0.07 | 0.15598 | 0.05 | 0.42978 | miRNAWalker2 validate | -0.18 | 0.03052 | ||
55 | hsa-miR-214-3p | CTNNB1 | -0.32 | 0 | 0.21 | 0.02055 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.29 | 0.02012 | 22962603; 22962603 | The enhancer of zeste homologue 2 EZH2 and β-catenin CTNNB1 was identified as two potential direct downstream targets of miR-214 through bioinformatics analysis and experimentally validated the miRNA-target interactions with a dual-firefly luciferase reporter assay;Furthermore the silencing of miR-214 or overexpression of EZH2 increased EpCAM+ stem-like cells through the activation of CTNNB1 |
56 | hsa-miR-215-5p | FZD1 | 0.04 | 0.21421 | -0.71 | 0 | miRNAWalker2 validate | -1.72 | 0 | ||
57 | hsa-miR-215-5p | FZD7 | 0.04 | 0.21421 | -0.29 | 0.05092 | miRNAWalker2 validate | -2.02 | 0 | ||
58 | hsa-miR-215-5p | PRICKLE1 | 0.04 | 0.21421 | -0.86 | 0 | miRNAWalker2 validate | -1.61 | 1.0E-5 | ||
59 | hsa-miR-215-5p | TCF7 | 0.04 | 0.21421 | 0.15 | 0.21177 | miRNAWalker2 validate; MirTarget | -0.62 | 0.02313 | ||
60 | hsa-miR-22-3p | CSNK2A1 | -0.08 | 0.02671 | 0.29 | 0.0016 | miRNAWalker2 validate | -1.01 | 0 | ||
61 | hsa-miR-22-3p | FRAT2 | -0.08 | 0.02671 | 0.03 | 0.70845 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.73 | 2.0E-5 | ||
62 | hsa-miR-221-3p | LRP6 | 0.19 | 0 | -0.15 | 0.01529 | miRNAWalker2 validate | -0.51 | 0 | ||
63 | hsa-miR-23b-3p | EP300 | 0.01 | 0.57764 | 0.11 | 0.05719 | miRNAWalker2 validate | -0.48 | 0.04041 | ||
64 | hsa-miR-24-3p | FZD5 | -0.01 | 0.59303 | 0.16 | 0.05185 | miRNAWalker2 validate; miRNATAP | -1.08 | 0.00069 | ||
65 | hsa-miR-26a-5p | CTBP1 | -0.08 | 7.0E-5 | 0.12 | 0.00038 | miRNAWalker2 validate | -0.41 | 0.0007 | ||
66 | hsa-miR-26a-5p | GSK3B | -0.08 | 7.0E-5 | 0.1 | 0.09041 | miRNAWalker2 validate; miRNATAP | -0.51 | 0.02109 | ||
67 | hsa-miR-26b-5p | EP300 | -0.05 | 0.04928 | 0.11 | 0.05719 | miRNAWalker2 validate; miRNATAP | -0.52 | 0.00197 | ||
68 | hsa-miR-26b-5p | RUVBL1 | -0.05 | 0.04928 | 0.32 | 1.0E-5 | miRNAWalker2 validate | -1.1 | 0 | ||
69 | hsa-miR-26b-5p | SFRP4 | -0.05 | 0.04928 | 0.72 | 0.01772 | miRNAWalker2 validate | -5.01 | 0 | ||
70 | hsa-miR-26b-5p | VANGL1 | -0.05 | 0.04928 | 0.11 | 0.21591 | miRNAWalker2 validate; mirMAP | -0.64 | 0.02298 | ||
71 | hsa-miR-26b-5p | VANGL2 | -0.05 | 0.04928 | -0.36 | 0.11321 | miRNAWalker2 validate; MirTarget | -2.8 | 3.0E-5 | ||
72 | hsa-miR-27b-3p | CCND3 | -0 | 0.86264 | -0.19 | 0.01071 | miRNAWalker2 validate | -0.68 | 0.01531 | ||
73 | hsa-miR-29a-3p | DKK1 | -0.02 | 0.42365 | 1.1 | 0.00028 | miRNAWalker2 validate; miRTarBase | -2.19 | 0.00661 | ||
74 | hsa-miR-301a-3p | CCND2 | 0.32 | 0 | -0.02 | 0.79963 | miRNAWalker2 validate | -0.21 | 0.0097 | ||
75 | hsa-miR-302a-3p | CCND1 | 0.02 | 0.58031 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP | -1.39 | 0.0002 | ||
76 | hsa-miR-302c-3p | CCND1 | 0.05 | 0.06697 | -0.49 | 0.00116 | miRNAWalker2 validate; miRTarBase | -1.51 | 0.00013 | ||
77 | hsa-miR-30a-3p | EP300 | 0.03 | 0.21224 | 0.11 | 0.05719 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.62 | 0.00011 | ||
78 | hsa-miR-30c-5p | CSNK1E | -0.05 | 0.0598 | 0.28 | 0.00101 | miRNAWalker2 validate | -1.74 | 0 | ||
79 | hsa-miR-30c-5p | EP300 | -0.05 | 0.0598 | 0.11 | 0.05719 | miRNAWalker2 validate | -0.71 | 1.0E-5 | ||
80 | hsa-miR-30c-5p | PLCB1 | -0.05 | 0.0598 | 0.8 | 0 | miRNAWalker2 validate | -3.75 | 0 | ||
81 | hsa-miR-30c-5p | RAC1 | -0.05 | 0.0598 | 0.12 | 0.00036 | miRNAWalker2 validate | -0.65 | 0 | ||
82 | hsa-miR-30c-5p | TBL1XR1 | -0.05 | 0.0598 | 0.19 | 0.03766 | miRNAWalker2 validate | -0.59 | 0.02717 | ||
83 | hsa-miR-320a | FRAT2 | 0.02 | 0.22623 | 0.03 | 0.70845 | miRNAWalker2 validate | -0.77 | 0.01126 | ||
84 | hsa-miR-324-3p | CSNK1A1 | 0.02 | 0.24561 | -0.14 | 0.02274 | miRNAWalker2 validate | -0.48 | 0.04209 | ||
85 | hsa-miR-324-3p | WNT9B | 0.02 | 0.24561 | -0.32 | 0.01981 | miRNAWalker2 validate | -1.33 | 0.01182 | ||
86 | hsa-miR-335-5p | FZD10 | 0.02 | 0.79934 | 0.21 | 0.03364 | miRNAWalker2 validate | -0.19 | 0.04285 | ||
87 | hsa-miR-335-5p | FZD8 | 0.02 | 0.79934 | -0.26 | 0.04869 | miRNAWalker2 validate | -0.34 | 0.00766 | ||
88 | hsa-miR-335-5p | PRICKLE2 | 0.02 | 0.79934 | -0.71 | 2.0E-5 | miRNAWalker2 validate | -0.33 | 0.04103 | ||
89 | hsa-miR-335-5p | VANGL2 | 0.02 | 0.79934 | -0.36 | 0.11321 | miRNAWalker2 validate | -0.54 | 0.0106 | ||
90 | hsa-miR-33a-5p | MAPK8 | 0.16 | 0 | -0.17 | 0.0118 | miRNAWalker2 validate | -0.91 | 0 | ||
91 | hsa-miR-34b-5p | MYC | 0.11 | 0.00023 | -0.48 | 0.01676 | miRNAWalker2 validate; miRTarBase | -2.38 | 0 | ||
92 | hsa-miR-34c-5p | MYC | 0.2 | 5.0E-5 | -0.48 | 0.01676 | miRNAWalker2 validate; miRTarBase; miRanda | -0.66 | 0.02032 | 22370637 | We demonstrate that Bmf Bcl-2-modifying factor is a target of miR-34c-5p and that its silencing together with that of c-myc a known target of miR-34c-5p contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation |
93 | hsa-miR-375 | PRKCA | -0.55 | 0 | 0.19 | 0.01548 | miRNAWalker2 validate | -0.18 | 0.00108 | 23497265 | The integrated analysis of miRNA and mRNA expression identified 35 known and novel target genes of miR-200c miR-205 and mir-375 including CFL2 LAMC1 TIMP2 ZEB1 CDH11 PRKCA PTPRJ PTPRM LDHB and SEC23A |
94 | hsa-miR-375 | RHOA | -0.55 | 0 | 0.09 | 4.0E-5 | miRNAWalker2 validate | -0.08 | 0 | ||
95 | hsa-miR-429 | TCF7L1 | -0.08 | 0.00239 | 0.03 | 0.57819 | miRNAWalker2 validate | -0.55 | 0.00092 | ||
96 | hsa-miR-7-5p | CAMK2D | 0.11 | 7.0E-5 | -0.2 | 0.00605 | miRNAWalker2 validate | -0.52 | 0.0053 | ||
97 | hsa-miR-7-5p | LRP6 | 0.11 | 7.0E-5 | -0.15 | 0.01529 | miRNAWalker2 validate; miRNATAP | -0.61 | 7.0E-5 | ||
98 | hsa-miR-9-5p | CCND1 | 0.21 | 0.00475 | -0.49 | 0.00116 | miRNAWalker2 validate | -0.51 | 0.00055 | ||
99 | hsa-miR-9-5p | NFATC3 | 0.21 | 0.00475 | -0.2 | 0.00031 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.16 | 0.00247 | ||
100 | hsa-miR-92a-3p | GSK3B | -0.03 | 0.37888 | 0.1 | 0.09041 | miRNAWalker2 validate | -0.51 | 0.00114 | ||
101 | hsa-miR-92a-3p | PPARD | -0.03 | 0.37888 | 0.12 | 0.01438 | miRNAWalker2 validate | -0.27 | 0.02806 | ||
102 | hsa-miR-92a-3p | PRKCA | -0.03 | 0.37888 | 0.19 | 0.01548 | miRNAWalker2 validate | -0.55 | 0.00495 | ||
103 | hsa-miR-93-5p | CCND1 | 0.19 | 0 | -0.49 | 0.00116 | miRNAWalker2 validate; MirTarget; miRNATAP | -1.94 | 0 | 25371073 | Furthermore miR-93 may downregulate the Wnt/β-catenin pathway which was confirmed by measuring the expression level of the β-catenin axin c-Myc and cyclin-D1 in this pathway |
104 | hsa-miR-93-5p | JUN | 0.19 | 0 | -0.5 | 5.0E-5 | miRNAWalker2 validate | -1.06 | 0.00026 | ||
105 | hsa-miR-135b-5p | APC | -0.11 | 0.00127 | 0.05 | 0.42978 | miRTarBase; MirTarget | -0.28 | 0.02881 | ||
106 | hsa-miR-100-5p | FZD5 | -0.14 | 0.00081 | 0.16 | 0.05185 | MirTarget; miRNATAP | -0.47 | 0.00056 | ||
107 | hsa-miR-101-3p | NLK | -0.13 | 4.0E-5 | 0.18 | 0.00757 | MirTarget; miRNATAP | -0.34 | 0.02683 | ||
108 | hsa-miR-103a-3p | WNT7A | 0.11 | 0 | -0.11 | 0.01687 | MirTarget | -0.3 | 0.02794 | ||
109 | hsa-miR-105-5p | PRICKLE2 | 0.17 | 0.00159 | -0.71 | 2.0E-5 | MirTarget; miRNATAP | -0.76 | 0.00048 | ||
110 | hsa-miR-105-5p | PRKX | 0.17 | 0.00159 | 0.03 | 0.73526 | MirTarget | -0.31 | 0.00608 | ||
111 | hsa-miR-106a-5p | CCND1 | 0.05 | 0.12421 | -0.49 | 0.00116 | MirTarget; miRNATAP | -1.17 | 0.00029 | ||
112 | hsa-miR-10a-5p | CAMK2G | -0.29 | 0 | 0.2 | 0.00105 | MirTarget; miRNATAP | -0.56 | 0 | ||
113 | hsa-miR-10b-5p | CAMK2G | -0.03 | 0.44052 | 0.2 | 0.00105 | MirTarget; miRNATAP | -0.34 | 0.00684 | ||
114 | hsa-miR-124-3p | NFATC2 | 0.08 | 0.04068 | -0.21 | 0.05152 | MirTarget; miRNATAP | -0.51 | 0.01381 | ||
115 | hsa-miR-125a-5p | CSNK2A1 | -0.13 | 0.00014 | 0.29 | 0.0016 | MirTarget; PITA; miRanda | -0.64 | 0.00109 | ||
116 | hsa-miR-125b-5p | CSNK2A1 | -0.19 | 1.0E-5 | 0.29 | 0.0016 | MirTarget; miRNATAP | -0.86 | 0 | ||
117 | hsa-miR-126-5p | PRKX | 0 | 0.93995 | 0.03 | 0.73526 | MirTarget; miRNATAP | -0.9 | 0.00101 | ||
118 | hsa-miR-126-5p | MAP3K7 | 0 | 0.93995 | 0.2 | 0.01129 | MirTarget | -0.94 | 0.00011 | ||
119 | hsa-miR-128-3p | PPP2R1B | 0.08 | 0.0018 | -0.02 | 0.78139 | MirTarget | -0.45 | 0.01384 | ||
120 | hsa-miR-128-3p | VANGL2 | 0.08 | 0.0018 | -0.36 | 0.11321 | MirTarget | -2.59 | 3.0E-5 | ||
121 | hsa-miR-128-3p | PRKX | 0.08 | 0.0018 | 0.03 | 0.73526 | MirTarget | -0.54 | 0.02703 | ||
122 | hsa-miR-129-5p | EP300 | -0.01 | 0.79472 | 0.11 | 0.05719 | MirTarget; PITA; miRanda; miRNATAP | -0.29 | 0.02668 | ||
123 | hsa-miR-130a-3p | TBL1XR1 | -0.19 | 0 | 0.19 | 0.03766 | MirTarget | -0.44 | 0.00429 | ||
124 | hsa-miR-130b-3p | FOSL1 | 0.19 | 4.0E-5 | -0.54 | 0.00109 | MirTarget | -1.34 | 0 | ||
125 | hsa-miR-130b-3p | DAAM1 | 0.19 | 4.0E-5 | -0.1 | 0.25736 | MirTarget; miRNATAP | -0.54 | 3.0E-5 | ||
126 | hsa-miR-136-5p | FZD4 | -0.05 | 0.32506 | 0.05 | 0.55827 | MirTarget | -0.3 | 0.00572 | ||
127 | hsa-miR-137 | MAP3K7 | 0.03 | 0.28838 | 0.2 | 0.01129 | MirTarget; miRanda | -0.5 | 0.00936 | ||
128 | hsa-miR-138-5p | DVL2 | -0.21 | 0.00013 | 0.39 | 0 | MirTarget; miRNATAP | -0.27 | 0.00652 | ||
129 | hsa-miR-138-5p | CAMK2A | -0.21 | 0.00013 | 0.15 | 0.05444 | MirTarget | -0.27 | 0.00921 | ||
130 | hsa-miR-139-5p | PRKX | -0.08 | 0.00239 | 0.03 | 0.73526 | MirTarget | -0.98 | 9.0E-5 | ||
131 | hsa-miR-139-5p | MAP3K7 | -0.08 | 0.00239 | 0.2 | 0.01129 | MirTarget | -1.25 | 0 | ||
132 | hsa-miR-139-5p | PPP3CB | -0.08 | 0.00239 | 0.2 | 0.00445 | MirTarget; PITA; miRanda | -0.65 | 0.00185 | ||
133 | hsa-miR-142-3p | TBL1X | -0.06 | 0.14584 | 0.31 | 0.00218 | MirTarget; PITA; miRanda; miRNATAP | -0.54 | 0.00184 | ||
134 | hsa-miR-143-3p | CSNK2A1 | -0.09 | 0.00824 | 0.29 | 0.0016 | MirTarget | -0.74 | 7.0E-5 | ||
135 | hsa-miR-143-3p | MAP3K7 | -0.09 | 0.00824 | 0.2 | 0.01129 | MirTarget; miRNATAP | -0.48 | 0.0026 | ||
136 | hsa-miR-144-3p | TBL1XR1 | -0.11 | 0.02244 | 0.19 | 0.03766 | MirTarget | -0.35 | 0.00894 | ||
137 | hsa-miR-144-3p | PRKX | -0.11 | 0.02244 | 0.03 | 0.73526 | MirTarget | -0.29 | 0.02356 | ||
138 | hsa-miR-145-5p | SENP2 | -0.2 | 0 | 0.15 | 0.009 | MirTarget | -0.42 | 3.0E-5 | ||
139 | hsa-miR-145-5p | SMAD2 | -0.2 | 0 | 0.23 | 0.00027 | MirTarget | -0.39 | 0.00037 | ||
140 | hsa-miR-146a-5p | RAC1 | -0.15 | 0.00019 | 0.12 | 0.00036 | MirTarget | -0.19 | 0.00158 | ||
141 | hsa-miR-147a | CCND1 | 0.09 | 0.00179 | -0.49 | 0.00116 | MirTarget | -2.3 | 0 | ||
142 | hsa-miR-147a | NFAT5 | 0.09 | 0.00179 | -0.12 | 0.30997 | MirTarget; miRNATAP | -0.61 | 0.0278 | ||
143 | hsa-miR-148a-3p | SMAD2 | -0.01 | 0.73806 | 0.23 | 0.00027 | MirTarget; mirMAP | -0.6 | 0 | ||
144 | hsa-miR-148a-3p | PRKX | -0.01 | 0.73806 | 0.03 | 0.73526 | MirTarget | -0.79 | 0 | ||
145 | hsa-miR-148b-3p | PRICKLE2 | 0.14 | 0 | -0.71 | 2.0E-5 | MirTarget; miRNATAP | -2.73 | 0 | ||
146 | hsa-miR-150-5p | DVL3 | -0.18 | 0.00075 | 0.11 | 0.00083 | MirTarget | -0.28 | 0 | ||
147 | hsa-miR-150-5p | NLK | -0.18 | 0.00075 | 0.18 | 0.00757 | MirTarget | -0.44 | 0 | ||
148 | hsa-miR-152-3p | PRICKLE2 | -0 | 0.97674 | -0.71 | 2.0E-5 | MirTarget | -0.99 | 0.0065 | ||
149 | hsa-miR-152-3p | SMAD2 | -0 | 0.97674 | 0.23 | 0.00027 | MirTarget | -0.63 | 0 | ||
150 | hsa-miR-152-3p | PRKX | -0 | 0.97674 | 0.03 | 0.73526 | MirTarget | -0.62 | 0.00095 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | WNT SIGNALING PATHWAY | 77 | 351 | 1.039e-106 | 4.836e-103 |
2 | CANONICAL WNT SIGNALING PATHWAY | 40 | 95 | 1.058e-65 | 2.462e-62 |
3 | NON CANONICAL WNT SIGNALING PATHWAY | 37 | 140 | 1.188e-51 | 1.842e-48 |
4 | REGULATION OF WNT SIGNALING PATHWAY | 45 | 310 | 1.781e-50 | 2.071e-47 |
5 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 33 | 236 | 4.847e-36 | 4.511e-33 |
6 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 66 | 1929 | 1.915e-35 | 1.273e-32 |
7 | NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 31 | 197 | 1.693e-35 | 1.273e-32 |
8 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 50 | 1021 | 7.638e-33 | 4.442e-30 |
9 | POSITIVE REGULATION OF CELL COMMUNICATION | 58 | 1532 | 1.049e-32 | 5.423e-30 |
10 | REGULATION OF ORGAN MORPHOGENESIS | 30 | 242 | 4.2e-31 | 1.954e-28 |
11 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 58 | 1672 | 1.146e-30 | 4.848e-28 |
12 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 18 | 39 | 1.768e-30 | 6.855e-28 |
13 | REGULATION OF PROTEIN MODIFICATION PROCESS | 58 | 1710 | 3.796e-30 | 1.359e-27 |
14 | TISSUE MORPHOGENESIS | 37 | 533 | 3.667e-29 | 1.219e-26 |
15 | POSITIVE REGULATION OF GENE EXPRESSION | 57 | 1733 | 7.631e-29 | 2.367e-26 |
16 | EPITHELIUM DEVELOPMENT | 45 | 945 | 9.362e-29 | 2.723e-26 |
17 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 55 | 1618 | 2.176e-28 | 5.956e-26 |
18 | MORPHOGENESIS OF AN EPITHELIUM | 33 | 400 | 2.335e-28 | 6.036e-26 |
19 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 53 | 1492 | 3.905e-28 | 9.564e-26 |
20 | TISSUE DEVELOPMENT | 53 | 1518 | 9.03e-28 | 2.101e-25 |
21 | ORGAN MORPHOGENESIS | 42 | 841 | 1.598e-27 | 3.542e-25 |
22 | NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 24 | 162 | 7.632e-27 | 1.614e-24 |
23 | BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY | 14 | 22 | 1.243e-26 | 2.515e-24 |
24 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 21 | 110 | 5.135e-26 | 9.956e-24 |
25 | TUBE MORPHOGENESIS | 29 | 323 | 5.977e-26 | 1.112e-23 |
26 | TUBE DEVELOPMENT | 33 | 552 | 7.265e-24 | 1.3e-21 |
27 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 43 | 1135 | 1.997e-23 | 3.441e-21 |
28 | REGULATION OF CELL DIFFERENTIATION | 48 | 1492 | 2.603e-23 | 4.325e-21 |
29 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 52 | 1805 | 2.851e-23 | 4.575e-21 |
30 | EMBRYONIC MORPHOGENESIS | 32 | 539 | 4.861e-23 | 7.539e-21 |
31 | NEURON DIFFERENTIATION | 38 | 874 | 1.23e-22 | 1.845e-20 |
32 | EMBRYO DEVELOPMENT | 38 | 894 | 2.72e-22 | 3.954e-20 |
33 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 40 | 1036 | 5.438e-22 | 7.442e-20 |
34 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 40 | 1036 | 5.438e-22 | 7.442e-20 |
35 | NEUROGENESIS | 45 | 1402 | 1.123e-21 | 1.493e-19 |
36 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 50 | 1791 | 1.166e-21 | 1.507e-19 |
37 | NEGATIVE REGULATION OF CELL COMMUNICATION | 42 | 1192 | 1.208e-21 | 1.519e-19 |
38 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 31 | 554 | 1.484e-21 | 1.817e-19 |
39 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 44 | 1360 | 2.737e-21 | 3.266e-19 |
40 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 41 | 1152 | 2.945e-21 | 3.426e-19 |
41 | REGULATION OF EMBRYONIC DEVELOPMENT | 18 | 114 | 7.862e-21 | 8.922e-19 |
42 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 26 | 365 | 1.027e-20 | 1.138e-18 |
43 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 30 | 552 | 1.691e-20 | 1.83e-18 |
44 | REGULATION OF CELL CYCLE | 37 | 949 | 2.063e-20 | 2.182e-18 |
45 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 37 | 957 | 2.736e-20 | 2.829e-18 |
46 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 34 | 788 | 4.431e-20 | 4.386e-18 |
47 | CIRCULATORY SYSTEM DEVELOPMENT | 34 | 788 | 4.431e-20 | 4.386e-18 |
48 | POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 19 | 152 | 6.14e-20 | 5.952e-18 |
49 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 48 | 1848 | 2.185e-19 | 2.075e-17 |
50 | PATTERN SPECIFICATION PROCESS | 26 | 418 | 3.066e-19 | 2.854e-17 |
51 | CELL FATE COMMITMENT | 21 | 227 | 3.505e-19 | 3.198e-17 |
52 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 45 | 1656 | 8.127e-19 | 7.135e-17 |
53 | REGULATION OF CELL PROLIFERATION | 43 | 1496 | 8.033e-19 | 7.135e-17 |
54 | REGIONALIZATION | 23 | 311 | 9.587e-19 | 8.261e-17 |
55 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 38 | 1142 | 1.24e-18 | 1.049e-16 |
56 | SENSORY ORGAN DEVELOPMENT | 27 | 493 | 1.503e-18 | 1.249e-16 |
57 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 33 | 823 | 1.611e-18 | 1.315e-16 |
58 | REGULATION OF BINDING | 22 | 283 | 2.014e-18 | 1.615e-16 |
59 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 46 | 1784 | 2.268e-18 | 1.789e-16 |
60 | REGULATION OF CELL DEATH | 42 | 1472 | 3.092e-18 | 2.398e-16 |
61 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 17 | 134 | 4.782e-18 | 3.648e-16 |
62 | DORSAL VENTRAL AXIS SPECIFICATION | 10 | 20 | 7.893e-18 | 5.923e-16 |
63 | REGULATION OF PROTEIN LOCALIZATION | 34 | 950 | 1.417e-17 | 1.046e-15 |
64 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 40 | 1395 | 2.168e-17 | 1.576e-15 |
65 | CELL PROLIFERATION | 29 | 672 | 4.069e-17 | 2.913e-15 |
66 | REGULATION OF CELLULAR RESPONSE TO STRESS | 29 | 691 | 8.514e-17 | 6.003e-15 |
67 | CELLULAR RESPONSE TO RETINOIC ACID | 13 | 65 | 9.465e-17 | 6.573e-15 |
68 | INTRACELLULAR SIGNAL TRANSDUCTION | 41 | 1572 | 2.122e-16 | 1.452e-14 |
69 | POSITIVE REGULATION OF CELL DEATH | 27 | 605 | 2.573e-16 | 1.735e-14 |
70 | EMBRYONIC ORGAN DEVELOPMENT | 23 | 406 | 3.417e-16 | 2.271e-14 |
71 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 30 | 801 | 4.978e-16 | 3.262e-14 |
72 | POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 15 | 119 | 5.335e-16 | 3.448e-14 |
73 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 33 | 1004 | 5.715e-16 | 3.642e-14 |
74 | HEART DEVELOPMENT | 24 | 466 | 6.141e-16 | 3.861e-14 |
75 | PROTEIN PHOSPHORYLATION | 32 | 944 | 7.334e-16 | 4.55e-14 |
76 | REGULATION OF RESPONSE TO STRESS | 39 | 1468 | 7.985e-16 | 4.889e-14 |
77 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 21 | 337 | 1.136e-15 | 6.867e-14 |
78 | REGULATION OF HYDROLASE ACTIVITY | 37 | 1327 | 1.206e-15 | 7.192e-14 |
79 | TUBE FORMATION | 15 | 129 | 1.834e-15 | 1.08e-13 |
80 | CELL DEVELOPMENT | 38 | 1426 | 1.914e-15 | 1.113e-13 |
81 | REGULATION OF JNK CASCADE | 16 | 159 | 2.063e-15 | 1.185e-13 |
82 | REGULATION OF CELLULAR LOCALIZATION | 36 | 1277 | 2.335e-15 | 1.325e-13 |
83 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 39 | 1517 | 2.366e-15 | 1.327e-13 |
84 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 39 | 1518 | 2.418e-15 | 1.34e-13 |
85 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 17 | 194 | 2.686e-15 | 1.47e-13 |
86 | RESPONSE TO RETINOIC ACID | 14 | 107 | 3.087e-15 | 1.67e-13 |
87 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 17 | 197 | 3.474e-15 | 1.858e-13 |
88 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 24 | 513 | 5.212e-15 | 2.756e-13 |
89 | SENSORY ORGAN MORPHOGENESIS | 18 | 239 | 5.564e-15 | 2.909e-13 |
90 | REGULATION OF TRANSFERASE ACTIVITY | 31 | 946 | 5.776e-15 | 2.986e-13 |
91 | EMBRYONIC ORGAN MORPHOGENESIS | 19 | 279 | 5.849e-15 | 2.991e-13 |
92 | SEGMENTATION | 13 | 89 | 7.182e-15 | 3.632e-13 |
93 | AXIS SPECIFICATION | 13 | 90 | 8.352e-15 | 4.147e-13 |
94 | NEGATIVE REGULATION OF GENE EXPRESSION | 38 | 1493 | 8.377e-15 | 4.147e-13 |
95 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 21 | 381 | 1.302e-14 | 6.376e-13 |
96 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 17 | 220 | 2.186e-14 | 1.06e-12 |
97 | GASTRULATION | 15 | 155 | 2.929e-14 | 1.405e-12 |
98 | EPITHELIAL TO MESENCHYMAL TRANSITION | 11 | 56 | 2.959e-14 | 1.405e-12 |
99 | REGULATION OF CELL CYCLE PROCESS | 24 | 558 | 3.308e-14 | 1.548e-12 |
100 | REGULATION OF PROTEIN TARGETING | 19 | 307 | 3.326e-14 | 1.548e-12 |
101 | SOMITE DEVELOPMENT | 12 | 78 | 4.274e-14 | 1.969e-12 |
102 | CELLULAR RESPONSE TO LIPID | 22 | 457 | 4.568e-14 | 2.064e-12 |
103 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 21 | 406 | 4.537e-14 | 2.064e-12 |
104 | DOPAMINERGIC NEURON DIFFERENTIATION | 9 | 28 | 5.033e-14 | 2.252e-12 |
105 | REGULATION OF ORGANELLE ORGANIZATION | 33 | 1178 | 5.523e-14 | 2.447e-12 |
106 | RESPONSE TO LIPID | 29 | 888 | 5.657e-14 | 2.461e-12 |
107 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 15 | 162 | 5.66e-14 | 2.461e-12 |
108 | BETA CATENIN TCF COMPLEX ASSEMBLY | 10 | 43 | 7.291e-14 | 3.141e-12 |
109 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 14 | 135 | 8.408e-14 | 3.589e-12 |
110 | NEGATIVE REGULATION OF CELL PROLIFERATION | 25 | 643 | 8.768e-14 | 3.709e-12 |
111 | REGULATION OF CELL DEVELOPMENT | 28 | 836 | 9.003e-14 | 3.774e-12 |
112 | SOMITOGENESIS | 11 | 62 | 9.799e-14 | 4.071e-12 |
113 | RESPONSE TO GROWTH FACTOR | 22 | 475 | 9.991e-14 | 4.114e-12 |
114 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 42 | 1977 | 1.035e-13 | 4.225e-12 |
115 | REGULATION OF KINASE ACTIVITY | 27 | 776 | 1.094e-13 | 4.425e-12 |
116 | REGULATION OF CYTOPLASMIC TRANSPORT | 22 | 481 | 1.287e-13 | 5.164e-12 |
117 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 35 | 1381 | 1.493e-13 | 5.936e-12 |
118 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 14 | 142 | 1.707e-13 | 6.731e-12 |
119 | REGULATION OF CELL MORPHOGENESIS | 23 | 552 | 2.355e-13 | 9.207e-12 |
120 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 26 | 740 | 2.697e-13 | 1.046e-11 |
121 | DORSAL VENTRAL PATTERN FORMATION | 12 | 91 | 2.907e-13 | 1.118e-11 |
122 | NEURAL TUBE DEVELOPMENT | 14 | 149 | 3.338e-13 | 1.271e-11 |
123 | REGULATION OF INTRACELLULAR TRANSPORT | 24 | 621 | 3.359e-13 | 1.271e-11 |
124 | REGULATION OF PROTEIN IMPORT | 15 | 183 | 3.431e-13 | 1.287e-11 |
125 | NEURAL TUBE FORMATION | 12 | 94 | 4.334e-13 | 1.613e-11 |
126 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 23 | 573 | 5.111e-13 | 1.887e-11 |
127 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 16 | 228 | 5.955e-13 | 2.148e-11 |
128 | MESENCHYME DEVELOPMENT | 15 | 190 | 5.949e-13 | 2.148e-11 |
129 | STEM CELL DIFFERENTIATION | 15 | 190 | 5.949e-13 | 2.148e-11 |
130 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 26 | 767 | 6.123e-13 | 2.192e-11 |
131 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 7 | 14 | 8.248e-13 | 2.929e-11 |
132 | PHOSPHORYLATION | 32 | 1228 | 1.034e-12 | 3.643e-11 |
133 | REGULATION OF MAPK CASCADE | 24 | 660 | 1.235e-12 | 4.32e-11 |
134 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 26 | 799 | 1.55e-12 | 5.381e-11 |
135 | POSITIVE REGULATION OF CELL CYCLE | 18 | 332 | 1.572e-12 | 5.419e-11 |
136 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 27 | 876 | 1.9e-12 | 6.501e-11 |
137 | REGULATION OF JUN KINASE ACTIVITY | 11 | 81 | 2.123e-12 | 7.211e-11 |
138 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 35 | 1527 | 2.727e-12 | 9.193e-11 |
139 | CELLULAR RESPONSE TO ACID CHEMICAL | 14 | 175 | 3.065e-12 | 1.019e-10 |
140 | RHYTHMIC PROCESS | 17 | 298 | 3.058e-12 | 1.019e-10 |
141 | REGULATION OF TRANSPORT | 38 | 1804 | 3.091e-12 | 1.02e-10 |
142 | CELL ACTIVATION | 22 | 568 | 3.532e-12 | 1.157e-10 |
143 | PALATE DEVELOPMENT | 11 | 85 | 3.661e-12 | 1.191e-10 |
144 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 13 | 144 | 4.073e-12 | 1.316e-10 |
145 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 15 | 218 | 4.38e-12 | 1.4e-10 |
146 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 10 | 63 | 4.392e-12 | 1.4e-10 |
147 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 28 | 983 | 4.522e-12 | 1.431e-10 |
148 | REPRODUCTIVE SYSTEM DEVELOPMENT | 19 | 408 | 5.19e-12 | 1.632e-10 |
149 | MACROMOLECULAR COMPLEX DISASSEMBLY | 14 | 182 | 5.233e-12 | 1.634e-10 |
150 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 18 | 360 | 6.102e-12 | 1.893e-10 |
151 | CELL CYCLE | 32 | 1316 | 6.502e-12 | 2.004e-10 |
152 | CELL DEATH | 28 | 1001 | 6.956e-12 | 2.111e-10 |
153 | MIDBRAIN DEVELOPMENT | 11 | 90 | 6.961e-12 | 2.111e-10 |
154 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 20 | 470 | 6.988e-12 | 2.111e-10 |
155 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 29 | 1079 | 7.182e-12 | 2.156e-10 |
156 | CELL CYCLE PROCESS | 29 | 1081 | 7.513e-12 | 2.241e-10 |
157 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 17 | 323 | 1.102e-11 | 3.266e-10 |
158 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 22 | 609 | 1.379e-11 | 4.062e-10 |
159 | MUSCLE STRUCTURE DEVELOPMENT | 19 | 432 | 1.399e-11 | 4.094e-10 |
160 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 22 | 616 | 1.722e-11 | 5.007e-10 |
161 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 13 | 167 | 2.694e-11 | 7.785e-10 |
162 | FC RECEPTOR SIGNALING PATHWAY | 14 | 206 | 2.792e-11 | 8.02e-10 |
163 | REGULATION OF PROTEIN BINDING | 13 | 168 | 2.905e-11 | 8.293e-10 |
164 | MESENCHYMAL CELL DIFFERENTIATION | 12 | 134 | 3.124e-11 | 8.863e-10 |
165 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 24 | 771 | 3.214e-11 | 9.063e-10 |
166 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 20 | 514 | 3.494e-11 | 9.793e-10 |
167 | HEAD DEVELOPMENT | 23 | 709 | 3.876e-11 | 1.08e-09 |
168 | HEART MORPHOGENESIS | 14 | 212 | 4.103e-11 | 1.136e-09 |
169 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 15 | 258 | 4.848e-11 | 1.335e-09 |
170 | REGULATION OF MITOTIC CELL CYCLE | 19 | 468 | 5.531e-11 | 1.514e-09 |
171 | POSITIVE REGULATION OF MAPK CASCADE | 19 | 470 | 5.948e-11 | 1.619e-09 |
172 | POSITIVE REGULATION OF CELL DEVELOPMENT | 19 | 472 | 6.395e-11 | 1.73e-09 |
173 | EMBRYONIC PATTERN SPECIFICATION | 9 | 58 | 6.668e-11 | 1.786e-09 |
174 | KIDNEY MORPHOGENESIS | 10 | 82 | 6.678e-11 | 1.786e-09 |
175 | NEGATIVE REGULATION OF CELL DEATH | 25 | 872 | 6.766e-11 | 1.799e-09 |
176 | REGULATION OF PROTEIN PHOSPHATASE TYPE 2A ACTIVITY | 7 | 24 | 7.912e-11 | 2.092e-09 |
177 | REGULATION OF STEM CELL DIFFERENTIATION | 11 | 113 | 8.659e-11 | 2.276e-09 |
178 | POSITIVE REGULATION OF KINASE ACTIVITY | 19 | 482 | 9.135e-11 | 2.382e-09 |
179 | REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 9 | 60 | 9.163e-11 | 2.382e-09 |
180 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 17 | 370 | 9.28e-11 | 2.399e-09 |
181 | RESPONSE TO ACID CHEMICAL | 16 | 319 | 9.529e-11 | 2.45e-09 |
182 | PROTEASOMAL PROTEIN CATABOLIC PROCESS | 15 | 271 | 9.69e-11 | 2.477e-09 |
183 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 23 | 750 | 1.181e-10 | 3.003e-09 |
184 | CONVERGENT EXTENSION | 6 | 14 | 1.249e-10 | 3.142e-09 |
185 | CELLULAR RESPONSE TO STRESS | 33 | 1565 | 1.249e-10 | 3.142e-09 |
186 | CELLULAR COMPONENT MORPHOGENESIS | 25 | 900 | 1.318e-10 | 3.279e-09 |
187 | EYE DEVELOPMENT | 16 | 326 | 1.313e-10 | 3.279e-09 |
188 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 15 | 282 | 1.692e-10 | 4.187e-09 |
189 | MESONEPHROS DEVELOPMENT | 10 | 90 | 1.715e-10 | 4.222e-09 |
190 | MITOTIC CELL CYCLE | 23 | 766 | 1.789e-10 | 4.374e-09 |
191 | DEVELOPMENTAL GROWTH | 16 | 333 | 1.796e-10 | 4.374e-09 |
192 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 11 | 121 | 1.826e-10 | 4.425e-09 |
193 | REGULATION OF CATENIN IMPORT INTO NUCLEUS | 7 | 27 | 2e-10 | 4.821e-09 |
194 | MESODERM MORPHOGENESIS | 9 | 66 | 2.226e-10 | 5.338e-09 |
195 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 15 | 289 | 2.382e-10 | 5.683e-09 |
196 | GLAND DEVELOPMENT | 17 | 395 | 2.55e-10 | 6.054e-09 |
197 | KIDNEY EPITHELIUM DEVELOPMENT | 11 | 125 | 2.599e-10 | 6.138e-09 |
198 | SINGLE ORGANISM CELL ADHESION | 18 | 459 | 3.254e-10 | 7.648e-09 |
199 | PARAXIAL MESODERM DEVELOPMENT | 6 | 16 | 3.298e-10 | 7.711e-09 |
200 | RESPONSE TO ENDOGENOUS STIMULUS | 31 | 1450 | 3.786e-10 | 8.809e-09 |
201 | UROGENITAL SYSTEM DEVELOPMENT | 15 | 299 | 3.82e-10 | 8.844e-09 |
202 | NEGATIVE REGULATION OF BINDING | 11 | 131 | 4.314e-10 | 9.887e-09 |
203 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 11 | 131 | 4.314e-10 | 9.887e-09 |
204 | DIGESTIVE TRACT MORPHOGENESIS | 8 | 48 | 4.378e-10 | 9.986e-09 |
205 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 171 | 5.407e-10 | 1.227e-08 |
206 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 8 | 50 | 6.167e-10 | 1.393e-08 |
207 | PROTEIN COMPLEX BIOGENESIS | 27 | 1132 | 6.283e-10 | 1.406e-08 |
208 | PROTEIN COMPLEX ASSEMBLY | 27 | 1132 | 6.283e-10 | 1.406e-08 |
209 | EMBRYONIC AXIS SPECIFICATION | 7 | 33 | 9.336e-10 | 2.079e-08 |
210 | NEGATIVE REGULATION OF CELL CYCLE | 17 | 433 | 1.037e-09 | 2.298e-08 |
211 | NEGATIVE REGULATION OF PROTEIN BINDING | 9 | 79 | 1.159e-09 | 2.556e-08 |
212 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 7 | 34 | 1.17e-09 | 2.567e-08 |
213 | FORMATION OF PRIMARY GERM LAYER | 10 | 110 | 1.27e-09 | 2.775e-08 |
214 | REGULATION OF GROWTH | 20 | 633 | 1.345e-09 | 2.924e-08 |
215 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 25 | 1008 | 1.382e-09 | 2.991e-08 |
216 | REGULATION OF PROTEOLYSIS | 21 | 711 | 1.655e-09 | 3.566e-08 |
217 | REGULATION OF PROTEIN CATABOLIC PROCESS | 16 | 393 | 1.993e-09 | 4.274e-08 |
218 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 14 | 285 | 2.005e-09 | 4.28e-08 |
219 | CELLULAR COMPONENT DISASSEMBLY | 18 | 515 | 2.031e-09 | 4.314e-08 |
220 | SKELETAL SYSTEM DEVELOPMENT | 17 | 455 | 2.192e-09 | 4.598e-08 |
221 | COCHLEA MORPHOGENESIS | 6 | 21 | 2.18e-09 | 4.598e-08 |
222 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 23 | 872 | 2.194e-09 | 4.598e-08 |
223 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 11 | 154 | 2.43e-09 | 5.071e-08 |
224 | MESODERM DEVELOPMENT | 10 | 118 | 2.535e-09 | 5.266e-08 |
225 | MESENCHYME MORPHOGENESIS | 7 | 38 | 2.69e-09 | 5.563e-08 |
226 | RESPIRATORY SYSTEM DEVELOPMENT | 12 | 197 | 2.732e-09 | 5.626e-08 |
227 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 16 | 404 | 2.959e-09 | 6.065e-08 |
228 | POSITIVE REGULATION OF CELL PROLIFERATION | 22 | 814 | 3.311e-09 | 6.758e-08 |
229 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 13 | 247 | 3.414e-09 | 6.937e-08 |
230 | REGULATION OF IMMUNE SYSTEM PROCESS | 29 | 1403 | 3.466e-09 | 6.981e-08 |
231 | VASCULATURE DEVELOPMENT | 17 | 469 | 3.453e-09 | 6.981e-08 |
232 | GROWTH | 16 | 410 | 3.651e-09 | 7.323e-08 |
233 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 19 | 602 | 3.704e-09 | 7.398e-08 |
234 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 23 | 905 | 4.437e-09 | 8.823e-08 |
235 | INNER EAR MORPHOGENESIS | 9 | 92 | 4.581e-09 | 9.071e-08 |
236 | LEUKOCYTE CELL CELL ADHESION | 13 | 255 | 5.014e-09 | 9.885e-08 |
237 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 20 | 684 | 5.038e-09 | 9.892e-08 |
238 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 15 | 363 | 5.416e-09 | 1.059e-07 |
239 | REGULATION OF PHOSPHATASE ACTIVITY | 10 | 128 | 5.61e-09 | 1.092e-07 |
240 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 8 | 67 | 6.877e-09 | 1.333e-07 |
241 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 13 | 263 | 7.264e-09 | 1.402e-07 |
242 | RESPONSE TO DRUG | 16 | 431 | 7.416e-09 | 1.426e-07 |
243 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 13 | 264 | 7.602e-09 | 1.456e-07 |
244 | POSITIVE REGULATION OF TRANSPORT | 23 | 936 | 8.355e-09 | 1.593e-07 |
245 | REGULATION OF MAP KINASE ACTIVITY | 14 | 319 | 8.476e-09 | 1.61e-07 |
246 | NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT | 6 | 26 | 9.025e-09 | 1.707e-07 |
247 | REGULATION OF CELL CYCLE PHASE TRANSITION | 14 | 321 | 9.175e-09 | 1.728e-07 |
248 | RESPONSE TO ABIOTIC STIMULUS | 24 | 1024 | 9.388e-09 | 1.761e-07 |
249 | EYE MORPHOGENESIS | 10 | 136 | 1.01e-08 | 1.886e-07 |
250 | RESPONSE TO CYTOKINE | 20 | 714 | 1.037e-08 | 1.931e-07 |
251 | DEVELOPMENTAL INDUCTION | 6 | 27 | 1.155e-08 | 2.132e-07 |
252 | AXIS ELONGATION | 6 | 27 | 1.155e-08 | 2.132e-07 |
253 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 9 | 103 | 1.252e-08 | 2.302e-07 |
254 | MACROMOLECULAR COMPLEX ASSEMBLY | 28 | 1398 | 1.365e-08 | 2.5e-07 |
255 | REGULATION OF CELL GROWTH | 15 | 391 | 1.465e-08 | 2.673e-07 |
256 | REGULATION OF CATABOLIC PROCESS | 20 | 731 | 1.536e-08 | 2.793e-07 |
257 | FAT CELL DIFFERENTIATION | 9 | 106 | 1.613e-08 | 2.921e-07 |
258 | REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 8 | 77 | 2.11e-08 | 3.805e-07 |
259 | MUSCLE CELL DIFFERENTIATION | 12 | 237 | 2.175e-08 | 3.908e-07 |
260 | RENAL TUBULE DEVELOPMENT | 8 | 78 | 2.339e-08 | 4.186e-07 |
261 | EAR MORPHOGENESIS | 9 | 112 | 2.619e-08 | 4.651e-07 |
262 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 9 | 112 | 2.619e-08 | 4.651e-07 |
263 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 7 | 53 | 3.048e-08 | 5.373e-07 |
264 | MESONEPHRIC TUBULE MORPHOGENESIS | 7 | 53 | 3.048e-08 | 5.373e-07 |
265 | NEPHRON DEVELOPMENT | 9 | 115 | 3.301e-08 | 5.797e-07 |
266 | REGULATION OF ORGAN FORMATION | 6 | 32 | 3.449e-08 | 6.032e-07 |
267 | FOREBRAIN DEVELOPMENT | 14 | 357 | 3.49e-08 | 6.081e-07 |
268 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 11 | 199 | 3.531e-08 | 6.131e-07 |
269 | NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 117 | 3.838e-08 | 6.615e-07 |
270 | MAMMARY GLAND DEVELOPMENT | 9 | 117 | 3.838e-08 | 6.615e-07 |
271 | POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT | 6 | 33 | 4.194e-08 | 7.201e-07 |
272 | REGULATION OF DEPHOSPHORYLATION | 10 | 158 | 4.245e-08 | 7.261e-07 |
273 | POSITIVE REGULATION OF PROTEOLYSIS | 14 | 363 | 4.294e-08 | 7.318e-07 |
274 | REGULATION OF CHROMATIN BINDING | 5 | 17 | 4.355e-08 | 7.368e-07 |
275 | ESTABLISHMENT OF TISSUE POLARITY | 5 | 17 | 4.355e-08 | 7.368e-07 |
276 | REGULATION OF IMMUNE RESPONSE | 21 | 858 | 4.374e-08 | 7.374e-07 |
277 | REGULATION OF CELL ADHESION | 18 | 629 | 4.446e-08 | 7.469e-07 |
278 | OUTFLOW TRACT MORPHOGENESIS | 7 | 56 | 4.518e-08 | 7.562e-07 |
279 | CELL CYCLE PHASE TRANSITION | 12 | 255 | 4.878e-08 | 8.135e-07 |
280 | REGULATION OF MESENCHYMAL CELL PROLIFERATION | 6 | 34 | 5.068e-08 | 8.392e-07 |
281 | BIOLOGICAL ADHESION | 23 | 1032 | 5.064e-08 | 8.392e-07 |
282 | EPITHELIAL CELL DIFFERENTIATION | 16 | 495 | 5.113e-08 | 8.437e-07 |
283 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 11 | 207 | 5.289e-08 | 8.697e-07 |
284 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 9 | 122 | 5.527e-08 | 9.056e-07 |
285 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 5 | 18 | 6e-08 | 9.797e-07 |
286 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 12 | 263 | 6.841e-08 | 1.113e-06 |
287 | STEM CELL PROLIFERATION | 7 | 60 | 7.375e-08 | 1.196e-06 |
288 | SEX DIFFERENTIATION | 12 | 266 | 7.743e-08 | 1.251e-06 |
289 | APPENDAGE DEVELOPMENT | 10 | 169 | 8.023e-08 | 1.287e-06 |
290 | LIMB DEVELOPMENT | 10 | 169 | 8.023e-08 | 1.287e-06 |
291 | IMMUNE SYSTEM DEVELOPMENT | 17 | 582 | 8.156e-08 | 1.304e-06 |
292 | NEGATIVE REGULATION OF CELL GROWTH | 10 | 170 | 8.482e-08 | 1.352e-06 |
293 | NEPHRON EPITHELIUM DEVELOPMENT | 8 | 93 | 9.422e-08 | 1.496e-06 |
294 | REGULATION OF CELL SUBSTRATE ADHESION | 10 | 173 | 9.998e-08 | 1.582e-06 |
295 | REGULATION OF MUSCLE ADAPTATION | 7 | 63 | 1.041e-07 | 1.642e-06 |
296 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 12 | 274 | 1.069e-07 | 1.681e-06 |
297 | COCHLEA DEVELOPMENT | 6 | 39 | 1.199e-07 | 1.879e-06 |
298 | REGULATION OF CHROMOSOME ORGANIZATION | 12 | 278 | 1.251e-07 | 1.953e-06 |
299 | REGULATION OF OSSIFICATION | 10 | 178 | 1.306e-07 | 2.032e-06 |
300 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 21 | 917 | 1.342e-07 | 2.081e-06 |
301 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 6 | 40 | 1.404e-07 | 2.164e-06 |
302 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 21 | 1.405e-07 | 2.164e-06 |
303 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 15 | 465 | 1.419e-07 | 2.18e-06 |
304 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 7 | 66 | 1.443e-07 | 2.209e-06 |
305 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 11 | 229 | 1.476e-07 | 2.251e-06 |
306 | CELL CELL ADHESION | 17 | 608 | 1.52e-07 | 2.312e-06 |
307 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 10 | 181 | 1.527e-07 | 2.314e-06 |
308 | IMMUNE SYSTEM PROCESS | 32 | 1984 | 1.671e-07 | 2.524e-06 |
309 | REGULATION OF CELL JUNCTION ASSEMBLY | 7 | 68 | 1.779e-07 | 2.679e-06 |
310 | CAMERA TYPE EYE MORPHOGENESIS | 8 | 101 | 1.796e-07 | 2.696e-06 |
311 | SOMATIC STEM CELL DIVISION | 5 | 22 | 1.809e-07 | 2.706e-06 |
312 | REPRODUCTION | 25 | 1297 | 1.988e-07 | 2.965e-06 |
313 | LOCOMOTION | 23 | 1114 | 2.002e-07 | 2.967e-06 |
314 | NEGATIVE REGULATION OF GROWTH | 11 | 236 | 1.998e-07 | 2.967e-06 |
315 | REGULATION OF MUSCLE TISSUE DEVELOPMENT | 8 | 103 | 2.092e-07 | 3.071e-06 |
316 | REGULATION OF CIRCADIAN RHYTHM | 8 | 103 | 2.092e-07 | 3.071e-06 |
317 | REGULATION OF MUSCLE ORGAN DEVELOPMENT | 8 | 103 | 2.092e-07 | 3.071e-06 |
318 | POSITIVE REGULATION OF GROWTH | 11 | 238 | 2.175e-07 | 3.182e-06 |
319 | MORPHOGENESIS OF AN EPITHELIAL SHEET | 6 | 43 | 2.198e-07 | 3.205e-06 |
320 | POSITIVE REGULATION OF PROTEIN IMPORT | 8 | 104 | 2.255e-07 | 3.268e-06 |
321 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 8 | 104 | 2.255e-07 | 3.268e-06 |
322 | PROTEIN DEPHOSPHORYLATION | 10 | 190 | 2.399e-07 | 3.467e-06 |
323 | BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS | 6 | 44 | 2.532e-07 | 3.647e-06 |
324 | REGULATION OF FAT CELL DIFFERENTIATION | 8 | 106 | 2.614e-07 | 3.753e-06 |
325 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 9 | 148 | 2.911e-07 | 4.118e-06 |
326 | PEPTIDYL SERINE MODIFICATION | 9 | 148 | 2.911e-07 | 4.118e-06 |
327 | DIGESTIVE SYSTEM DEVELOPMENT | 9 | 148 | 2.911e-07 | 4.118e-06 |
328 | RESPONSE TO EXTERNAL STIMULUS | 30 | 1821 | 2.891e-07 | 4.118e-06 |
329 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 5 | 24 | 2.892e-07 | 4.118e-06 |
330 | RESPONSE TO ALCOHOL | 13 | 362 | 3.046e-07 | 4.295e-06 |
331 | POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY | 10 | 197 | 3.355e-07 | 4.716e-06 |
332 | REGULATION OF CYTOSKELETON ORGANIZATION | 15 | 502 | 3.778e-07 | 5.294e-06 |
333 | REGULATION OF CELLULAR RESPONSE TO HEAT | 7 | 76 | 3.855e-07 | 5.386e-06 |
334 | SKELETAL SYSTEM MORPHOGENESIS | 10 | 201 | 4.038e-07 | 5.626e-06 |
335 | POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 4 | 11 | 4.071e-07 | 5.654e-06 |
336 | IN UTERO EMBRYONIC DEVELOPMENT | 12 | 311 | 4.174e-07 | 5.78e-06 |
337 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 12 | 312 | 4.319e-07 | 5.928e-06 |
338 | ANTERIOR POSTERIOR AXIS SPECIFICATION | 6 | 48 | 4.316e-07 | 5.928e-06 |
339 | POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 6 | 48 | 4.316e-07 | 5.928e-06 |
340 | CARDIAC SEPTUM MORPHOGENESIS | 6 | 49 | 4.894e-07 | 6.697e-06 |
341 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 6 | 50 | 5.534e-07 | 7.551e-06 |
342 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 11 | 262 | 5.663e-07 | 7.704e-06 |
343 | NEGATIVE REGULATION OF LOCOMOTION | 11 | 263 | 5.88e-07 | 7.977e-06 |
344 | REGULATION OF FIBROBLAST PROLIFERATION | 7 | 81 | 5.98e-07 | 8.088e-06 |
345 | SKIN DEVELOPMENT | 10 | 211 | 6.307e-07 | 8.506e-06 |
346 | VENTRICULAR SEPTUM MORPHOGENESIS | 5 | 28 | 6.558e-07 | 8.793e-06 |
347 | MORPHOGENESIS OF A POLARIZED EPITHELIUM | 5 | 28 | 6.558e-07 | 8.793e-06 |
348 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 9 | 166 | 7.676e-07 | 1.023e-05 |
349 | POSITIVE REGULATION OF OSSIFICATION | 7 | 84 | 7.674e-07 | 1.023e-05 |
350 | EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 8 | 122 | 7.7e-07 | 1.024e-05 |
351 | STEM CELL DIVISION | 5 | 29 | 7.886e-07 | 1.045e-05 |
352 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 167 | 8.073e-07 | 1.067e-05 |
353 | T CELL DIFFERENTIATION | 8 | 123 | 8.195e-07 | 1.08e-05 |
354 | CELL CELL SIGNALING | 18 | 767 | 8.284e-07 | 1.089e-05 |
355 | CARDIAC SEPTUM DEVELOPMENT | 7 | 85 | 8.321e-07 | 1.091e-05 |
356 | WOUND HEALING | 14 | 470 | 9.865e-07 | 1.282e-05 |
357 | REGULATION OF KIDNEY DEVELOPMENT | 6 | 55 | 9.849e-07 | 1.282e-05 |
358 | RESPONSE TO UV | 8 | 126 | 9.844e-07 | 1.282e-05 |
359 | REGULATION OF STEM CELL PROLIFERATION | 7 | 88 | 1.054e-06 | 1.366e-05 |
360 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 8 | 128 | 1.109e-06 | 1.434e-05 |
361 | REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 5 | 31 | 1.117e-06 | 1.44e-05 |
362 | LYMPHOCYTE ACTIVATION | 12 | 342 | 1.138e-06 | 1.462e-05 |
363 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 8 | 129 | 1.177e-06 | 1.508e-05 |
364 | REGULATION OF CELL MATRIX ADHESION | 7 | 90 | 1.228e-06 | 1.57e-05 |
365 | RESPONSE TO INORGANIC SUBSTANCE | 14 | 479 | 1.234e-06 | 1.573e-05 |
366 | LEUKOCYTE ACTIVATION | 13 | 414 | 1.378e-06 | 1.752e-05 |
367 | MAINTENANCE OF CELL NUMBER | 8 | 132 | 1.4e-06 | 1.776e-05 |
368 | REGULATION OF DEVELOPMENTAL GROWTH | 11 | 289 | 1.482e-06 | 1.869e-05 |
369 | APOPTOTIC SIGNALING PATHWAY | 11 | 289 | 1.482e-06 | 1.869e-05 |
370 | REGULATION OF DNA BINDING | 7 | 93 | 1.535e-06 | 1.93e-05 |
371 | REGULATION OF CYTOKINE PRODUCTION | 15 | 563 | 1.587e-06 | 1.985e-05 |
372 | RESPONSE TO WOUNDING | 15 | 563 | 1.587e-06 | 1.985e-05 |
373 | RESPONSE TO HORMONE | 19 | 893 | 1.715e-06 | 2.139e-05 |
374 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 7 | 95 | 1.772e-06 | 2.199e-05 |
375 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 7 | 95 | 1.772e-06 | 2.199e-05 |
376 | REGULATION OF PROTEIN DEACETYLATION | 5 | 34 | 1.804e-06 | 2.226e-05 |
377 | BRAIN MORPHOGENESIS | 5 | 34 | 1.804e-06 | 2.226e-05 |
378 | EMBRYONIC DIGIT MORPHOGENESIS | 6 | 61 | 1.832e-06 | 2.255e-05 |
379 | MITOTIC CELL CYCLE CHECKPOINT | 8 | 139 | 2.067e-06 | 2.538e-05 |
380 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 21 | 1087 | 2.13e-06 | 2.608e-05 |
381 | BLOOD VESSEL MORPHOGENESIS | 12 | 364 | 2.176e-06 | 2.658e-05 |
382 | CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 4 | 16 | 2.193e-06 | 2.671e-05 |
383 | REGULATION OF CARTILAGE DEVELOPMENT | 6 | 63 | 2.219e-06 | 2.689e-05 |
384 | REGULATION OF EPIDERMIS DEVELOPMENT | 6 | 63 | 2.219e-06 | 2.689e-05 |
385 | PROTEIN CATABOLIC PROCESS | 15 | 579 | 2.24e-06 | 2.708e-05 |
386 | ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 8 | 141 | 2.301e-06 | 2.774e-05 |
387 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 11 | 303 | 2.344e-06 | 2.819e-05 |
388 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 36 | 2.42e-06 | 2.902e-05 |
389 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 7 | 100 | 2.504e-06 | 2.995e-05 |
390 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 12 | 370 | 2.576e-06 | 3.074e-05 |
391 | CARDIAC CHAMBER DEVELOPMENT | 8 | 144 | 2.694e-06 | 3.206e-05 |
392 | RESPONSE TO EXTRACELLULAR STIMULUS | 13 | 441 | 2.765e-06 | 3.282e-05 |
393 | CONNECTIVE TISSUE DEVELOPMENT | 9 | 194 | 2.799e-06 | 3.314e-05 |
394 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 2.854e-06 | 3.362e-05 |
395 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 4 | 17 | 2.854e-06 | 3.362e-05 |
396 | SOMATIC STEM CELL POPULATION MAINTENANCE | 6 | 66 | 2.924e-06 | 3.419e-05 |
397 | CELLULAR RESPONSE TO UV | 6 | 66 | 2.924e-06 | 3.419e-05 |
398 | EAR DEVELOPMENT | 9 | 195 | 2.92e-06 | 3.419e-05 |
399 | REGULATION OF PROTEIN COMPLEX ASSEMBLY | 12 | 375 | 2.958e-06 | 3.45e-05 |
400 | REGULATION OF GTPASE ACTIVITY | 16 | 673 | 3.038e-06 | 3.533e-05 |
401 | CARDIAC CHAMBER MORPHOGENESIS | 7 | 104 | 3.257e-06 | 3.78e-05 |
402 | MALE SEX DIFFERENTIATION | 8 | 148 | 3.305e-06 | 3.826e-05 |
403 | PERICARDIUM DEVELOPMENT | 4 | 18 | 3.653e-06 | 4.197e-05 |
404 | POST ANAL TAIL MORPHOGENESIS | 4 | 18 | 3.653e-06 | 4.197e-05 |
405 | UTERUS DEVELOPMENT | 4 | 18 | 3.653e-06 | 4.197e-05 |
406 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 7 | 106 | 3.7e-06 | 4.24e-05 |
407 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 8 | 152 | 4.031e-06 | 4.608e-05 |
408 | REGULATION OF MEIOTIC CELL CYCLE | 5 | 40 | 4.143e-06 | 4.702e-05 |
409 | NEURAL PRECURSOR CELL PROLIFERATION | 6 | 70 | 4.138e-06 | 4.702e-05 |
410 | REGULATION OF MEMBRANE PERMEABILITY | 6 | 70 | 4.138e-06 | 4.702e-05 |
411 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 7 | 108 | 4.191e-06 | 4.745e-05 |
412 | CELL DIVISION | 13 | 460 | 4.378e-06 | 4.944e-05 |
413 | SKIN EPIDERMIS DEVELOPMENT | 6 | 71 | 4.497e-06 | 5.067e-05 |
414 | REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 4 | 19 | 4.605e-06 | 5.176e-05 |
415 | NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION | 5 | 41 | 4.696e-06 | 5.265e-05 |
416 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 8 | 156 | 4.887e-06 | 5.466e-05 |
417 | POSITIVE REGULATION OF CATABOLIC PROCESS | 12 | 395 | 5.032e-06 | 5.615e-05 |
418 | LYMPHOCYTE DIFFERENTIATION | 9 | 209 | 5.144e-06 | 5.726e-05 |
419 | GENITALIA DEVELOPMENT | 5 | 42 | 5.305e-06 | 5.891e-05 |
420 | NEURON PROJECTION DEVELOPMENT | 14 | 545 | 5.511e-06 | 6.105e-05 |
421 | TONGUE DEVELOPMENT | 4 | 20 | 5.73e-06 | 6.303e-05 |
422 | TRACHEA DEVELOPMENT | 4 | 20 | 5.73e-06 | 6.303e-05 |
423 | POSITIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 4 | 20 | 5.73e-06 | 6.303e-05 |
424 | RESPONSE TO METAL ION | 11 | 333 | 5.785e-06 | 6.348e-05 |
425 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 43 | 5.974e-06 | 6.54e-05 |
426 | REGULATION OF NEURON DIFFERENTIATION | 14 | 554 | 6.641e-06 | 7.254e-05 |
427 | LABYRINTHINE LAYER DEVELOPMENT | 5 | 44 | 6.707e-06 | 7.309e-05 |
428 | REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 218 | 7.236e-06 | 7.83e-05 |
429 | REGULATION OF CELL PROJECTION ORGANIZATION | 14 | 558 | 7.206e-06 | 7.83e-05 |
430 | REGULATION OF BMP SIGNALING PATHWAY | 6 | 77 | 7.228e-06 | 7.83e-05 |
431 | THYMOCYTE AGGREGATION | 5 | 45 | 7.509e-06 | 8.088e-05 |
432 | T CELL DIFFERENTIATION IN THYMUS | 5 | 45 | 7.509e-06 | 8.088e-05 |
433 | REGULATION OF PROTEIN STABILITY | 9 | 221 | 8.079e-06 | 8.682e-05 |
434 | PEPTIDYL THREONINE MODIFICATION | 5 | 46 | 8.385e-06 | 8.989e-05 |
435 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 7 | 121 | 8.896e-06 | 9.516e-05 |
436 | POSITIVE REGULATION OF LOCOMOTION | 12 | 420 | 9.353e-06 | 9.981e-05 |
437 | DEPHOSPHORYLATION | 10 | 286 | 9.568e-06 | 0.0001019 |
438 | SCF DEPENDENT PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 4 | 23 | 1.033e-05 | 0.0001097 |
439 | JNK CASCADE | 6 | 82 | 1.042e-05 | 0.0001104 |
440 | HAIR CYCLE | 6 | 83 | 1.117e-05 | 0.0001179 |
441 | MOLTING CYCLE | 6 | 83 | 1.117e-05 | 0.0001179 |
442 | POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION | 8 | 175 | 1.137e-05 | 0.0001197 |
443 | LEUKOCYTE DIFFERENTIATION | 10 | 292 | 1.146e-05 | 0.0001204 |
444 | OSTEOBLAST DIFFERENTIATION | 7 | 126 | 1.16e-05 | 0.0001216 |
445 | REGULATION OF HISTONE DEACETYLATION | 4 | 24 | 1.233e-05 | 0.0001287 |
446 | POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 4 | 24 | 1.233e-05 | 0.0001287 |
447 | MUSCLE CELL DEVELOPMENT | 7 | 128 | 1.286e-05 | 0.0001339 |
448 | REGULATION OF REPRODUCTIVE PROCESS | 7 | 129 | 1.353e-05 | 0.0001405 |
449 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 12 | 437 | 1.39e-05 | 0.000144 |
450 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 5 | 51 | 1.403e-05 | 0.000145 |
451 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 11 | 368 | 1.478e-05 | 0.0001525 |
452 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 10 | 303 | 1.578e-05 | 0.0001625 |
453 | RESPONSE TO NITROGEN COMPOUND | 17 | 859 | 1.637e-05 | 0.0001682 |
454 | EPITHELIAL CELL PROLIFERATION | 6 | 89 | 1.67e-05 | 0.0001712 |
455 | REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE | 5 | 53 | 1.697e-05 | 0.0001735 |
456 | NEURON DEVELOPMENT | 15 | 687 | 1.737e-05 | 0.0001773 |
457 | EPITHELIAL CELL DEVELOPMENT | 8 | 186 | 1.769e-05 | 0.0001801 |
458 | CALCIUM MEDIATED SIGNALING | 6 | 90 | 1.781e-05 | 0.0001805 |
459 | ENDOTHELIUM DEVELOPMENT | 6 | 90 | 1.781e-05 | 0.0001805 |
460 | POSITIVE REGULATION OF CELL ADHESION | 11 | 376 | 1.804e-05 | 0.0001825 |
461 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 17 | 867 | 1.844e-05 | 0.0001861 |
462 | VENTRICULAR SEPTUM DEVELOPMENT | 5 | 54 | 1.861e-05 | 0.0001875 |
463 | CELLULAR RESPONSE TO LIGHT STIMULUS | 6 | 91 | 1.897e-05 | 0.0001906 |
464 | CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS | 8 | 188 | 1.911e-05 | 0.0001916 |
465 | RESPONSE TO OXYGEN LEVELS | 10 | 311 | 1.974e-05 | 0.0001976 |
466 | CELLULAR RESPONSE TO RADIATION | 7 | 137 | 2.001e-05 | 0.0001997 |
467 | RESPONSE TO LITHIUM ION | 4 | 27 | 2.009e-05 | 0.0001997 |
468 | POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 4 | 27 | 2.009e-05 | 0.0001997 |
469 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 6 | 92 | 2.019e-05 | 0.0002003 |
470 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 8 | 190 | 2.062e-05 | 0.0002042 |
471 | CELL CYCLE G2 M PHASE TRANSITION | 7 | 138 | 2.098e-05 | 0.0002068 |
472 | PLACENTA DEVELOPMENT | 7 | 138 | 2.098e-05 | 0.0002068 |
473 | EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS | 6 | 93 | 2.148e-05 | 0.0002113 |
474 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 14 | 616 | 2.178e-05 | 0.0002138 |
475 | POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 8 | 192 | 2.224e-05 | 0.0002173 |
476 | OSSIFICATION | 9 | 251 | 2.228e-05 | 0.0002173 |
477 | PROTEIN AUTOPHOSPHORYLATION | 8 | 192 | 2.224e-05 | 0.0002173 |
478 | GASTRULATION WITH MOUTH FORMING SECOND | 4 | 28 | 2.332e-05 | 0.000227 |
479 | EPIDERMIS DEVELOPMENT | 9 | 253 | 2.372e-05 | 0.0002304 |
480 | PROTEIN LOCALIZATION | 26 | 1805 | 2.396e-05 | 0.0002318 |
481 | CELL CYCLE CHECKPOINT | 8 | 194 | 2.395e-05 | 0.0002318 |
482 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 13 | 541 | 2.454e-05 | 0.0002364 |
483 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 13 | 541 | 2.454e-05 | 0.0002364 |
484 | TAXIS | 12 | 464 | 2.511e-05 | 0.0002414 |
485 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 2.693e-05 | 0.0002573 |
486 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 2.693e-05 | 0.0002573 |
487 | REGULATION OF HEART MORPHOGENESIS | 4 | 29 | 2.693e-05 | 0.0002573 |
488 | NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 7 | 144 | 2.76e-05 | 0.0002632 |
489 | SYNAPSE ORGANIZATION | 7 | 145 | 2.886e-05 | 0.0002746 |
490 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 7 | 146 | 3.016e-05 | 0.0002864 |
491 | CELL PROJECTION ORGANIZATION | 17 | 902 | 3.047e-05 | 0.0002887 |
492 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 6 | 99 | 3.066e-05 | 0.00029 |
493 | POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 5 | 60 | 3.123e-05 | 0.0002947 |
494 | CARTILAGE DEVELOPMENT | 7 | 147 | 3.151e-05 | 0.0002962 |
495 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 7 | 147 | 3.151e-05 | 0.0002962 |
496 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 724 | 3.19e-05 | 0.0002992 |
497 | POSITIVE REGULATION OF CELL GROWTH | 7 | 148 | 3.292e-05 | 0.0003082 |
498 | NEURON PROJECTION MORPHOGENESIS | 11 | 402 | 3.332e-05 | 0.0003113 |
499 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 5 | 61 | 3.385e-05 | 0.0003156 |
500 | ENDOTHELIAL TUBE MORPHOGENESIS | 3 | 11 | 3.44e-05 | 0.0003195 |
501 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 11 | 3.44e-05 | 0.0003195 |
502 | NEURON PROJECTION GUIDANCE | 8 | 205 | 3.552e-05 | 0.0003292 |
503 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 6 | 102 | 3.631e-05 | 0.0003358 |
504 | PROTEOLYSIS | 20 | 1208 | 3.65e-05 | 0.000337 |
505 | REGULATION OF SMOOTHENED SIGNALING PATHWAY | 5 | 62 | 3.664e-05 | 0.0003376 |
506 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 8 | 207 | 3.806e-05 | 0.0003498 |
507 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 11 | 408 | 3.812e-05 | 0.0003498 |
508 | REGULATION OF CHROMATIN ORGANIZATION | 7 | 152 | 3.904e-05 | 0.0003576 |
509 | EMBRYONIC FORELIMB MORPHOGENESIS | 4 | 32 | 4.021e-05 | 0.0003675 |
510 | NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 8 | 209 | 4.074e-05 | 0.000371 |
511 | PALLIUM DEVELOPMENT | 7 | 153 | 4.071e-05 | 0.000371 |
512 | REGULATION OF CELL DIVISION | 9 | 272 | 4.177e-05 | 0.0003796 |
513 | RESPONSE TO MECHANICAL STIMULUS | 8 | 210 | 4.215e-05 | 0.0003823 |
514 | CELL CYCLE ARREST | 7 | 154 | 4.244e-05 | 0.0003841 |
515 | RESPONSE TO RADIATION | 11 | 413 | 4.256e-05 | 0.0003845 |
516 | POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 3 | 12 | 4.567e-05 | 0.0004094 |
517 | TRACHEA MORPHOGENESIS | 3 | 12 | 4.567e-05 | 0.0004094 |
518 | EMBRYONIC EYE MORPHOGENESIS | 4 | 33 | 4.554e-05 | 0.0004094 |
519 | MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 3 | 12 | 4.567e-05 | 0.0004094 |
520 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 8 | 213 | 4.66e-05 | 0.0004169 |
521 | PEPTIDYL AMINO ACID MODIFICATION | 16 | 841 | 4.766e-05 | 0.0004256 |
522 | MUSCLE ORGAN DEVELOPMENT | 9 | 277 | 4.811e-05 | 0.0004285 |
523 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 8 | 214 | 4.816e-05 | 0.0004285 |
524 | CELLULAR MACROMOLECULE LOCALIZATION | 20 | 1234 | 4.92e-05 | 0.0004369 |
525 | FOREBRAIN GENERATION OF NEURONS | 5 | 66 | 4.964e-05 | 0.00044 |
526 | PROTEIN DESTABILIZATION | 4 | 34 | 5.137e-05 | 0.0004544 |
527 | RESPONSE TO LIGHT STIMULUS | 9 | 280 | 5.228e-05 | 0.0004616 |
528 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 5 | 67 | 5.339e-05 | 0.0004687 |
529 | CELLULAR RESPONSE TO DRUG | 5 | 67 | 5.339e-05 | 0.0004687 |
530 | REGULATION OF SISTER CHROMATID SEGREGATION | 5 | 67 | 5.339e-05 | 0.0004687 |
531 | SECOND MESSENGER MEDIATED SIGNALING | 7 | 160 | 5.411e-05 | 0.0004741 |
532 | BONE REMODELING | 4 | 35 | 5.773e-05 | 0.0005049 |
533 | CELL CYCLE G1 S PHASE TRANSITION | 6 | 111 | 5.841e-05 | 0.000509 |
534 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 6 | 111 | 5.841e-05 | 0.000509 |
535 | WHITE FAT CELL DIFFERENTIATION | 3 | 13 | 5.91e-05 | 0.0005102 |
536 | HEMATOPOIETIC STEM CELL PROLIFERATION | 3 | 13 | 5.91e-05 | 0.0005102 |
537 | REGULATION OF SKELETAL MUSCLE ADAPTATION | 3 | 13 | 5.91e-05 | 0.0005102 |
538 | REGULATION OF CELL FATE SPECIFICATION | 3 | 13 | 5.91e-05 | 0.0005102 |
539 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 3 | 13 | 5.91e-05 | 0.0005102 |
540 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 7 | 163 | 6.086e-05 | 0.0005244 |
541 | POSITIVE REGULATION OF AXONOGENESIS | 5 | 69 | 6.153e-05 | 0.0005282 |
542 | SYNAPSE ASSEMBLY | 5 | 69 | 6.153e-05 | 0.0005282 |
543 | HEAD MORPHOGENESIS | 4 | 36 | 6.464e-05 | 0.0005539 |
544 | MUSCLE ORGAN MORPHOGENESIS | 5 | 70 | 6.594e-05 | 0.000564 |
545 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 6 | 114 | 6.779e-05 | 0.0005788 |
546 | REGULATION OF EPITHELIAL CELL MIGRATION | 7 | 166 | 6.829e-05 | 0.0005819 |
547 | NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 5 | 71 | 7.06e-05 | 0.0005994 |
548 | ENDODERM DEVELOPMENT | 5 | 71 | 7.06e-05 | 0.0005994 |
549 | CELLULAR RESPONSE TO ALCOHOL | 6 | 115 | 7.117e-05 | 0.0006021 |
550 | RESPONSE TO CALCIUM ION | 6 | 115 | 7.117e-05 | 0.0006021 |
551 | REGULATION OF MUSCLE HYPERTROPHY | 4 | 37 | 7.214e-05 | 0.0006092 |
552 | REGULATION OF AXONOGENESIS | 7 | 168 | 7.364e-05 | 0.0006207 |
553 | ANGIOGENESIS | 9 | 293 | 7.41e-05 | 0.0006235 |
554 | POSITIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 14 | 7.489e-05 | 0.0006267 |
555 | EMBRYONIC SKELETAL JOINT DEVELOPMENT | 3 | 14 | 7.489e-05 | 0.0006267 |
556 | REGULATION OF MONOCYTE DIFFERENTIATION | 3 | 14 | 7.489e-05 | 0.0006267 |
557 | TELENCEPHALON DEVELOPMENT | 8 | 228 | 7.516e-05 | 0.0006279 |
558 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 20 | 1275 | 7.738e-05 | 0.0006452 |
559 | SPECIFICATION OF SYMMETRY | 6 | 117 | 7.834e-05 | 0.0006499 |
560 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 13 | 606 | 7.836e-05 | 0.0006499 |
561 | CELLULAR RESPONSE TO STARVATION | 6 | 117 | 7.834e-05 | 0.0006499 |
562 | POSITIVE REGULATION OF PROTEIN BINDING | 5 | 73 | 8.067e-05 | 0.0006655 |
563 | PANCREAS DEVELOPMENT | 5 | 73 | 8.067e-05 | 0.0006655 |
564 | EMBRYONIC HEART TUBE DEVELOPMENT | 5 | 73 | 8.067e-05 | 0.0006655 |
565 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 8 | 232 | 8.485e-05 | 0.0006976 |
566 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 8 | 232 | 8.485e-05 | 0.0006976 |
567 | REGULATION OF VASCULATURE DEVELOPMENT | 8 | 233 | 8.743e-05 | 0.0007175 |
568 | STRIATED MUSCLE CELL DIFFERENTIATION | 7 | 173 | 8.853e-05 | 0.0007252 |
569 | NEURAL CREST CELL DIFFERENTIATION | 5 | 75 | 9.18e-05 | 0.0007507 |
570 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 3 | 15 | 9.32e-05 | 0.0007595 |
571 | REGULATION OF MESODERM DEVELOPMENT | 3 | 15 | 9.32e-05 | 0.0007595 |
572 | FORELIMB MORPHOGENESIS | 4 | 40 | 9.844e-05 | 0.0008007 |
573 | MITOCHONDRIAL TRANSPORT | 7 | 177 | 0.0001021 | 0.0008294 |
574 | NEGATIVE REGULATION OF TRANSPORT | 11 | 458 | 0.0001071 | 0.0008684 |
575 | MORPHOGENESIS OF AN ENDOTHELIUM | 3 | 16 | 0.0001142 | 0.0009209 |
576 | ORGAN INDUCTION | 3 | 16 | 0.0001142 | 0.0009209 |
577 | APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 3 | 16 | 0.0001142 | 0.0009209 |
578 | NEGATIVE REGULATION OF BMP SIGNALING PATHWAY | 4 | 42 | 0.0001194 | 0.0009598 |
579 | EPITHELIAL CELL MORPHOGENESIS | 4 | 42 | 0.0001194 | 0.0009598 |
580 | CHROMOSOME ORGANIZATION | 17 | 1009 | 0.0001212 | 0.0009726 |
581 | POSITIVE REGULATION OF BINDING | 6 | 127 | 0.0001233 | 0.0009873 |
582 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 5 | 80 | 0.0001248 | 0.000998 |
583 | REGULATION OF MYELOID CELL DIFFERENTIATION | 7 | 183 | 0.0001257 | 0.001003 |
584 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 8 | 246 | 0.0001273 | 0.001014 |
585 | HEPATICOBILIARY SYSTEM DEVELOPMENT | 6 | 128 | 0.0001287 | 0.001024 |
586 | REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 4 | 43 | 0.0001311 | 0.001039 |
587 | REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 4 | 43 | 0.0001311 | 0.001039 |
588 | CELLULAR RESPONSE TO HORMONE STIMULUS | 12 | 552 | 0.0001322 | 0.001046 |
589 | METANEPHROS DEVELOPMENT | 5 | 81 | 0.0001324 | 0.001046 |
590 | CELL JUNCTION ORGANIZATION | 7 | 185 | 0.0001345 | 0.00106 |
591 | CELLULAR RESPONSE TO LITHIUM ION | 3 | 17 | 0.0001381 | 0.001085 |
592 | NEGATIVE REGULATION OF STEM CELL PROLIFERATION | 3 | 17 | 0.0001381 | 0.001085 |
593 | BODY MORPHOGENESIS | 4 | 44 | 0.0001435 | 0.001126 |
594 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 15 | 829 | 0.0001455 | 0.00114 |
595 | MACROMOLECULE CATABOLIC PROCESS | 16 | 926 | 0.0001466 | 0.001146 |
596 | EMBRYONIC PLACENTA DEVELOPMENT | 5 | 83 | 0.0001486 | 0.00116 |
597 | REGULATION OF HORMONE LEVELS | 11 | 478 | 0.0001557 | 0.001214 |
598 | POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 5 | 84 | 0.0001573 | 0.001219 |
599 | NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 5 | 84 | 0.0001573 | 0.001219 |
600 | CELL MOTILITY | 15 | 835 | 0.0001574 | 0.001219 |
601 | LOCALIZATION OF CELL | 15 | 835 | 0.0001574 | 0.001219 |
602 | NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 7 | 191 | 0.0001638 | 0.001266 |
603 | REGULATION OF CELL MATURATION | 3 | 18 | 0.0001649 | 0.001273 |
604 | REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 85 | 0.0001663 | 0.001277 |
605 | REGULATION OF CHROMOSOME SEGREGATION | 5 | 85 | 0.0001663 | 0.001277 |
606 | POSITIVE REGULATION OF CHROMATIN MODIFICATION | 5 | 85 | 0.0001663 | 0.001277 |
607 | REGULATION OF PEPTIDE TRANSPORT | 8 | 256 | 0.0001673 | 0.001283 |
608 | REGULATION OF CHONDROCYTE DIFFERENTIATION | 4 | 46 | 0.0001709 | 0.001306 |
609 | EMBRYONIC CRANIAL SKELETON MORPHOGENESIS | 4 | 46 | 0.0001709 | 0.001306 |
610 | NEGATIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 135 | 0.0001723 | 0.001314 |
611 | NEGATIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 6 | 136 | 0.0001793 | 0.001366 |
612 | REGULATION OF MUSCLE SYSTEM PROCESS | 7 | 195 | 0.0001861 | 0.001412 |
613 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 47 | 0.0001859 | 0.001412 |
614 | CHROMATIN ORGANIZATION | 13 | 663 | 0.0001909 | 0.001447 |
615 | REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 3 | 19 | 0.000195 | 0.001473 |
616 | POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 3 | 19 | 0.000195 | 0.001473 |
617 | REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 4 | 48 | 0.0002019 | 0.001523 |
618 | RESPONSE TO STEROID HORMONE | 11 | 497 | 0.0002181 | 0.001642 |
619 | PLATELET ACTIVATION | 6 | 142 | 0.0002267 | 0.001704 |
620 | REGULATION OF DNA METABOLIC PROCESS | 9 | 340 | 0.000227 | 0.001704 |
621 | METANEPHRIC EPITHELIUM DEVELOPMENT | 3 | 20 | 0.0002284 | 0.001709 |
622 | BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS | 3 | 20 | 0.0002284 | 0.001709 |
623 | REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT | 4 | 50 | 0.0002368 | 0.001754 |
624 | CELLULAR RESPONSE TO OXYGEN LEVELS | 6 | 143 | 0.0002355 | 0.001754 |
625 | RAS PROTEIN SIGNAL TRANSDUCTION | 6 | 143 | 0.0002355 | 0.001754 |
626 | FACE DEVELOPMENT | 4 | 50 | 0.0002368 | 0.001754 |
627 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 50 | 0.0002368 | 0.001754 |
628 | RHO PROTEIN SIGNAL TRANSDUCTION | 4 | 50 | 0.0002368 | 0.001754 |
629 | ACTIVATION OF INNATE IMMUNE RESPONSE | 7 | 204 | 0.0002452 | 0.001814 |
630 | NEGATIVE REGULATION OF PHOSPHORYLATION | 10 | 422 | 0.0002478 | 0.00183 |
631 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 11 | 505 | 0.0002501 | 0.001844 |
632 | COVALENT CHROMATIN MODIFICATION | 9 | 345 | 0.0002529 | 0.001862 |
633 | RESPONSE TO ESTRADIOL | 6 | 146 | 0.0002634 | 0.001936 |
634 | APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 3 | 21 | 0.0002653 | 0.001944 |
635 | BONE RESORPTION | 3 | 21 | 0.0002653 | 0.001944 |
636 | POSITIVE REGULATION OF REPRODUCTIVE PROCESS | 4 | 52 | 0.0002757 | 0.002017 |
637 | NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 5 | 95 | 0.0002799 | 0.002045 |
638 | G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 18 | 1193 | 0.0002958 | 0.002157 |
639 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 4 | 53 | 0.0002969 | 0.002162 |
640 | MODULATION OF TRANSCRIPTION IN OTHER ORGANISM INVOLVED IN SYMBIOTIC INTERACTION | 3 | 22 | 0.0003058 | 0.002213 |
641 | POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 3 | 22 | 0.0003058 | 0.002213 |
642 | POSITIVE REGULATION OF CARDIAC MUSCLE HYPERTROPHY | 3 | 22 | 0.0003058 | 0.002213 |
643 | EMBRYONIC PLACENTA MORPHOGENESIS | 3 | 22 | 0.0003058 | 0.002213 |
644 | PROTEIN LOCALIZATION TO CELL PERIPHERY | 6 | 151 | 0.0003157 | 0.002281 |
645 | REGULATION OF SECRETION | 13 | 699 | 0.0003182 | 0.002296 |
646 | POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 5 | 98 | 0.0003234 | 0.002329 |
647 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 152 | 0.0003271 | 0.002352 |
648 | CRANIAL SKELETAL SYSTEM DEVELOPMENT | 4 | 55 | 0.0003425 | 0.00246 |
649 | DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 7 | 216 | 0.0003468 | 0.002486 |
650 | AMEBOIDAL TYPE CELL MIGRATION | 6 | 154 | 0.0003508 | 0.002499 |
651 | REGULATION OF OSTEOBLAST PROLIFERATION | 3 | 23 | 0.0003502 | 0.002499 |
652 | REGULATION OF METANEPHROS DEVELOPMENT | 3 | 23 | 0.0003502 | 0.002499 |
653 | RESPONSE TO STARVATION | 6 | 154 | 0.0003508 | 0.002499 |
654 | RESPONSE TO ESTROGEN | 7 | 218 | 0.0003666 | 0.002608 |
655 | SMAD PROTEIN SIGNAL TRANSDUCTION | 4 | 56 | 0.0003672 | 0.002608 |
656 | REGULATION OF EXTENT OF CELL GROWTH | 5 | 101 | 0.0003718 | 0.002637 |
657 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 6 | 156 | 0.0003758 | 0.002661 |
658 | MYOTUBE DIFFERENTIATION | 4 | 57 | 0.0003931 | 0.002775 |
659 | APOPTOTIC MITOCHONDRIAL CHANGES | 4 | 57 | 0.0003931 | 0.002775 |
660 | EMBRYONIC CAMERA TYPE EYE MORPHOGENESIS | 3 | 24 | 0.0003984 | 0.002805 |
661 | CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 24 | 0.0003984 | 0.002805 |
662 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 5 | 103 | 0.000407 | 0.002861 |
663 | PROTEIN ACYLATION | 6 | 159 | 0.0004159 | 0.002919 |
664 | CHROMATIN MODIFICATION | 11 | 539 | 0.0004342 | 0.003043 |
665 | REGENERATION | 6 | 161 | 0.0004445 | 0.003097 |
666 | CEREBRAL CORTEX DEVELOPMENT | 5 | 105 | 0.0004447 | 0.003097 |
667 | REGULATION OF DNA REPLICATION | 6 | 161 | 0.0004445 | 0.003097 |
668 | ODONTOGENESIS | 5 | 105 | 0.0004447 | 0.003097 |
669 | LENS FIBER CELL DIFFERENTIATION | 3 | 25 | 0.0004508 | 0.003103 |
670 | SPINDLE CHECKPOINT | 3 | 25 | 0.0004508 | 0.003103 |
671 | FOREBRAIN REGIONALIZATION | 3 | 25 | 0.0004508 | 0.003103 |
672 | REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 4 | 59 | 0.0004487 | 0.003103 |
673 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 3 | 25 | 0.0004508 | 0.003103 |
674 | REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 3 | 25 | 0.0004508 | 0.003103 |
675 | POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 3 | 25 | 0.0004508 | 0.003103 |
676 | VASCULOGENESIS | 4 | 59 | 0.0004487 | 0.003103 |
677 | REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 6 | 162 | 0.0004593 | 0.003157 |
678 | CELL PART MORPHOGENESIS | 12 | 633 | 0.0004603 | 0.003159 |
679 | CARDIAC VENTRICLE DEVELOPMENT | 5 | 106 | 0.0004644 | 0.003183 |
680 | REGULATION OF NUCLEAR DIVISION | 6 | 163 | 0.0004746 | 0.003247 |
681 | NEGATIVE REGULATION OF CELL DIVISION | 4 | 60 | 0.0004785 | 0.003265 |
682 | CHONDROCYTE DIFFERENTIATION | 4 | 60 | 0.0004785 | 0.003265 |
683 | CELL SUBSTRATE ADHESION | 6 | 164 | 0.0004902 | 0.003339 |
684 | MODULATION OF SYNAPTIC TRANSMISSION | 8 | 301 | 0.0004962 | 0.003376 |
685 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 0.0005073 | 0.003431 |
686 | NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT | 3 | 26 | 0.0005073 | 0.003431 |
687 | REGULATION OF CELL CYCLE ARREST | 5 | 108 | 0.000506 | 0.003431 |
688 | REGULATION OF CELL FATE COMMITMENT | 3 | 26 | 0.0005073 | 0.003431 |
689 | REGULATION OF CELL CELL ADHESION | 9 | 380 | 0.000511 | 0.003451 |
690 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 5 | 109 | 0.0005278 | 0.003554 |
691 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 0.0005278 | 0.003554 |
692 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 7 | 232 | 0.0005319 | 0.003576 |
693 | EMBRYONIC HEART TUBE MORPHOGENESIS | 4 | 62 | 0.0005423 | 0.003641 |
694 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 7 | 233 | 0.0005457 | 0.003658 |
695 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 8 | 306 | 0.000553 | 0.003702 |
696 | SKELETAL MUSCLE TISSUE REGENERATION | 3 | 27 | 0.0005682 | 0.003782 |
697 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 3 | 27 | 0.0005682 | 0.003782 |
698 | NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION | 3 | 27 | 0.0005682 | 0.003782 |
699 | NEGATIVE REGULATION OF AXON GUIDANCE | 3 | 27 | 0.0005682 | 0.003782 |
700 | COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 5 | 111 | 0.0005735 | 0.003812 |
701 | NEUROEPITHELIAL CELL DIFFERENTIATION | 4 | 63 | 0.0005764 | 0.003826 |
702 | REGULATION OF SYNAPSE ORGANIZATION | 5 | 113 | 0.0006221 | 0.004123 |
703 | POSITIVE REGULATION OF IMMUNE RESPONSE | 11 | 563 | 0.0006237 | 0.004128 |
704 | PLACENTA BLOOD VESSEL DEVELOPMENT | 3 | 28 | 0.0006336 | 0.004158 |
705 | NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 3 | 28 | 0.0006336 | 0.004158 |
706 | NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 3 | 28 | 0.0006336 | 0.004158 |
707 | REGULATION OF CELL SIZE | 6 | 172 | 0.0006301 | 0.004158 |
708 | MAMMARY GLAND DUCT MORPHOGENESIS | 3 | 28 | 0.0006336 | 0.004158 |
709 | METANEPHROS MORPHOGENESIS | 3 | 28 | 0.0006336 | 0.004158 |
710 | NEGATIVE REGULATION OF AXONOGENESIS | 4 | 65 | 0.0006491 | 0.004254 |
711 | RESPONSE TO INTERLEUKIN 1 | 5 | 115 | 0.0006737 | 0.004409 |
712 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 12 | 662 | 0.0006834 | 0.00446 |
713 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 12 | 662 | 0.0006834 | 0.00446 |
714 | REGULATION OF MICROTUBULE BASED PROCESS | 7 | 243 | 0.0006996 | 0.004559 |
715 | FEMALE SEX DIFFERENTIATION | 5 | 116 | 0.0007007 | 0.00456 |
716 | REGULATION OF MEIOTIC NUCLEAR DIVISION | 3 | 29 | 0.0007036 | 0.004566 |
717 | EMBRYONIC HINDLIMB MORPHOGENESIS | 3 | 29 | 0.0007036 | 0.004566 |
718 | POSITIVE REGULATION OF NEURON DEATH | 4 | 67 | 0.0007281 | 0.004708 |
719 | NEGATIVE REGULATION OF CYTOPLASMIC TRANSPORT | 5 | 117 | 0.0007285 | 0.004708 |
720 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 4 | 67 | 0.0007281 | 0.004708 |
721 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 5 | 118 | 0.0007571 | 0.004886 |
722 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 4 | 68 | 0.00077 | 0.004955 |
723 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 4 | 68 | 0.00077 | 0.004955 |
724 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 3 | 30 | 0.0007784 | 0.004961 |
725 | ESTABLISHMENT OR MAINTENANCE OF EPITHELIAL CELL APICAL BASAL POLARITY | 3 | 30 | 0.0007784 | 0.004961 |
726 | SMOOTH MUSCLE CELL DIFFERENTIATION | 3 | 30 | 0.0007784 | 0.004961 |
727 | POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 30 | 0.0007784 | 0.004961 |
728 | ESTABLISHMENT OF ENDOTHELIAL BARRIER | 3 | 30 | 0.0007784 | 0.004961 |
729 | RESPONSE TO X RAY | 3 | 30 | 0.0007784 | 0.004961 |
730 | MYOTUBE CELL DEVELOPMENT | 3 | 30 | 0.0007784 | 0.004961 |
731 | REGULATION OF CHEMOTAXIS | 6 | 180 | 0.0007991 | 0.005086 |
732 | RESPONSE TO KETONE | 6 | 182 | 0.0008464 | 0.00538 |
733 | INTERFERON GAMMA MEDIATED SIGNALING PATHWAY | 4 | 70 | 0.0008589 | 0.005452 |
734 | CELLULAR RESPONSE TO INTERFERON GAMMA | 5 | 122 | 0.0008799 | 0.005578 |
735 | CATABOLIC PROCESS | 22 | 1773 | 0.0008999 | 0.005697 |
736 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 4 | 71 | 0.000906 | 0.005727 |
737 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 5 | 123 | 0.0009128 | 0.005763 |
738 | PATTERNING OF BLOOD VESSELS | 3 | 32 | 0.0009426 | 0.005927 |
739 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 3 | 32 | 0.0009426 | 0.005927 |
740 | POSITIVE REGULATION OF EPIDERMIS DEVELOPMENT | 3 | 32 | 0.0009426 | 0.005927 |
741 | ENDOTHELIAL CELL DIFFERENTIATION | 4 | 72 | 0.0009548 | 0.005996 |
742 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 12 | 689 | 0.0009667 | 0.006062 |
743 | G1 DNA DAMAGE CHECKPOINT | 4 | 73 | 0.001005 | 0.006288 |
744 | REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 4 | 73 | 0.001005 | 0.006288 |
745 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 126 | 0.001017 | 0.006352 |
746 | REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 3 | 33 | 0.001032 | 0.006439 |
747 | REGULATION OF DENDRITE MORPHOGENESIS | 4 | 74 | 0.001058 | 0.006573 |
748 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 0.001058 | 0.006573 |
749 | CELL CELL JUNCTION ASSEMBLY | 4 | 74 | 0.001058 | 0.006573 |
750 | MEMBRANE ORGANIZATION | 14 | 899 | 0.00108 | 0.0067 |
751 | REGULATION OF HORMONE SECRETION | 7 | 262 | 0.001086 | 0.006726 |
752 | PROTEIN ACETYLATION | 5 | 129 | 0.00113 | 0.006972 |
753 | NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 3 | 34 | 0.001127 | 0.006972 |
754 | CELL JUNCTION ASSEMBLY | 5 | 129 | 0.00113 | 0.006972 |
755 | ACTIVATION OF IMMUNE RESPONSE | 9 | 427 | 0.001165 | 0.00718 |
756 | PROTEIN STABILIZATION | 5 | 131 | 0.00121 | 0.007448 |
757 | REGULATION OF GASTRULATION | 3 | 35 | 0.001227 | 0.007505 |
758 | DIENCEPHALON DEVELOPMENT | 4 | 77 | 0.001227 | 0.007505 |
759 | RESPONSE TO MINERALOCORTICOID | 3 | 35 | 0.001227 | 0.007505 |
760 | EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 3 | 35 | 0.001227 | 0.007505 |
761 | INNER EAR RECEPTOR CELL DEVELOPMENT | 3 | 35 | 0.001227 | 0.007505 |
762 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 4 | 78 | 0.001288 | 0.007862 |
763 | T CELL PROLIFERATION | 3 | 36 | 0.001333 | 0.008098 |
764 | NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT | 3 | 36 | 0.001333 | 0.008098 |
765 | NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 3 | 36 | 0.001333 | 0.008098 |
766 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 36 | 0.001333 | 0.008098 |
767 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 8 | 352 | 0.001364 | 0.008276 |
768 | NEGATIVE REGULATION OF VASCULATURE DEVELOPMENT | 4 | 80 | 0.001414 | 0.008569 |
769 | MUSCLE TISSUE DEVELOPMENT | 7 | 275 | 0.001434 | 0.008661 |
770 | HINDLIMB MORPHOGENESIS | 3 | 37 | 0.001444 | 0.008661 |
771 | REGULATION OF RECEPTOR INTERNALIZATION | 3 | 37 | 0.001444 | 0.008661 |
772 | MYOBLAST DIFFERENTIATION | 3 | 37 | 0.001444 | 0.008661 |
773 | REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 3 | 37 | 0.001444 | 0.008661 |
774 | NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 3 | 37 | 0.001444 | 0.008661 |
775 | ESTABLISHMENT OR MAINTENANCE OF APICAL BASAL CELL POLARITY | 3 | 37 | 0.001444 | 0.008661 |
776 | ESTABLISHMENT OR MAINTENANCE OF BIPOLAR CELL POLARITY | 3 | 37 | 0.001444 | 0.008661 |
777 | CIRCADIAN RHYTHM | 5 | 137 | 0.001476 | 0.008827 |
778 | HINDBRAIN DEVELOPMENT | 5 | 137 | 0.001476 | 0.008827 |
779 | POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 4 | 81 | 0.001481 | 0.008846 |
780 | PLASMA MEMBRANE ORGANIZATION | 6 | 203 | 0.001484 | 0.008852 |
781 | REGULATION OF INNATE IMMUNE RESPONSE | 8 | 357 | 0.001491 | 0.008885 |
782 | NEGATIVE REGULATION OF AXON EXTENSION | 3 | 38 | 0.001561 | 0.009255 |
783 | POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 3 | 38 | 0.001561 | 0.009255 |
784 | SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 3 | 38 | 0.001561 | 0.009255 |
785 | REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 3 | 38 | 0.001561 | 0.009255 |
786 | REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 7 | 280 | 0.00159 | 0.009411 |
787 | NIK NF KAPPAB SIGNALING | 4 | 83 | 0.001621 | 0.009582 |
788 | REGULATION OF SYNAPTIC PLASTICITY | 5 | 140 | 0.001624 | 0.009589 |
789 | POSITIVE REGULATION OF VIRAL TRANSCRIPTION | 3 | 39 | 0.001684 | 0.009898 |
790 | REGULATION OF AXON GUIDANCE | 3 | 39 | 0.001684 | 0.009898 |
791 | TRABECULA MORPHOGENESIS | 3 | 39 | 0.001684 | 0.009898 |
792 | POSITIVE REGULATION OF DEFENSE RESPONSE | 8 | 364 | 0.001685 | 0.009898 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | FRIZZLED BINDING | 20 | 36 | 5.593e-36 | 5.196e-33 |
2 | WNT PROTEIN BINDING | 15 | 31 | 6.011e-26 | 2.792e-23 |
3 | WNT ACTIVATED RECEPTOR ACTIVITY | 13 | 22 | 3.56e-24 | 1.102e-21 |
4 | BETA CATENIN BINDING | 16 | 84 | 5.237e-20 | 1.216e-17 |
5 | G PROTEIN COUPLED RECEPTOR BINDING | 20 | 259 | 9.274e-17 | 1.723e-14 |
6 | ENZYME BINDING | 41 | 1737 | 6.642e-15 | 1.028e-12 |
7 | TRANSCRIPTION FACTOR BINDING | 23 | 524 | 7.934e-14 | 1.053e-11 |
8 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 21 | 445 | 2.699e-13 | 3.134e-11 |
9 | PROTEIN DOMAIN SPECIFIC BINDING | 24 | 624 | 3.725e-13 | 3.845e-11 |
10 | RECEPTOR BINDING | 35 | 1476 | 1.03e-12 | 9.568e-11 |
11 | RECEPTOR AGONIST ACTIVITY | 7 | 16 | 2.722e-12 | 2.107e-10 |
12 | MOLECULAR FUNCTION REGULATOR | 33 | 1353 | 2.56e-12 | 2.107e-10 |
13 | SIGNAL TRANSDUCER ACTIVITY | 37 | 1731 | 4.278e-12 | 3.057e-10 |
14 | PROTEIN PHOSPHATASE TYPE 2A REGULATOR ACTIVITY | 7 | 21 | 2.698e-11 | 1.79e-09 |
15 | PROTEIN KINASE ACTIVITY | 22 | 640 | 3.604e-11 | 2.232e-09 |
16 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 15 | 264 | 6.706e-11 | 3.894e-09 |
17 | RECEPTOR REGULATOR ACTIVITY | 8 | 45 | 2.539e-10 | 1.387e-08 |
18 | SMAD BINDING | 9 | 72 | 4.965e-10 | 2.563e-08 |
19 | RECEPTOR ACTIVATOR ACTIVITY | 7 | 32 | 7.393e-10 | 3.615e-08 |
20 | I SMAD BINDING | 5 | 11 | 3.347e-09 | 1.555e-07 |
21 | REGULATORY REGION NUCLEIC ACID BINDING | 22 | 818 | 3.622e-09 | 1.602e-07 |
22 | KINASE BINDING | 19 | 606 | 4.127e-09 | 1.743e-07 |
23 | KINASE ACTIVITY | 22 | 842 | 6.134e-09 | 2.478e-07 |
24 | ARMADILLO REPEAT DOMAIN BINDING | 5 | 13 | 9.234e-09 | 3.574e-07 |
25 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 9 | 104 | 1.364e-08 | 5.067e-07 |
26 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 14 | 371 | 5.627e-08 | 1.936e-06 |
27 | PHOSPHATASE REGULATOR ACTIVITY | 8 | 87 | 5.572e-08 | 1.936e-06 |
28 | PDZ DOMAIN BINDING | 8 | 90 | 7.281e-08 | 2.416e-06 |
29 | PROTEIN DIMERIZATION ACTIVITY | 24 | 1149 | 8.346e-08 | 2.674e-06 |
30 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 7 | 64 | 1.163e-07 | 3.485e-06 |
31 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 22 | 992 | 1.128e-07 | 3.485e-06 |
32 | R SMAD BINDING | 5 | 23 | 2.3e-07 | 6.678e-06 |
33 | ENZYME REGULATOR ACTIVITY | 21 | 959 | 2.821e-07 | 7.94e-06 |
34 | MAP KINASE ACTIVITY | 4 | 14 | 1.218e-06 | 3.24e-05 |
35 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 6 | 57 | 1.221e-06 | 3.24e-05 |
36 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 16 | 629 | 1.269e-06 | 3.275e-05 |
37 | CALMODULIN BINDING | 9 | 179 | 1.44e-06 | 3.616e-05 |
38 | RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING | 5 | 36 | 2.42e-06 | 5.916e-05 |
39 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 15 | 588 | 2.706e-06 | 6.445e-05 |
40 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 11 | 315 | 3.406e-06 | 7.911e-05 |
41 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 11 | 328 | 5.011e-06 | 0.0001135 |
42 | RHO GTPASE BINDING | 6 | 78 | 7.792e-06 | 0.0001724 |
43 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 21 | 1199 | 9.738e-06 | 0.0002056 |
44 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 9 | 226 | 9.671e-06 | 0.0002056 |
45 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 8 | 172 | 1.002e-05 | 0.0002069 |
46 | IDENTICAL PROTEIN BINDING | 21 | 1209 | 1.105e-05 | 0.0002231 |
47 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 8 | 178 | 1.286e-05 | 0.0002543 |
48 | CHROMATIN BINDING | 12 | 435 | 1.328e-05 | 0.000257 |
49 | PHOSPHORIC ESTER HYDROLASE ACTIVITY | 11 | 368 | 1.478e-05 | 0.0002771 |
50 | DOUBLE STRANDED DNA BINDING | 16 | 764 | 1.492e-05 | 0.0002771 |
51 | CALMODULIN DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 28 | 2.332e-05 | 0.0004249 |
52 | PROTEIN HOMODIMERIZATION ACTIVITY | 15 | 722 | 3.09e-05 | 0.000552 |
53 | GAMMA CATENIN BINDING | 3 | 12 | 4.567e-05 | 0.0008004 |
54 | SEQUENCE SPECIFIC DNA BINDING | 18 | 1037 | 5.121e-05 | 0.000881 |
55 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING | 3 | 15 | 9.32e-05 | 0.001574 |
56 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 92 | 0.000241 | 0.003999 |
57 | PHOSPHATASE ACTIVITY | 8 | 275 | 0.0002719 | 0.004431 |
58 | ADENYL NUCLEOTIDE BINDING | 21 | 1514 | 0.0002793 | 0.004474 |
59 | RIBONUCLEOTIDE BINDING | 24 | 1860 | 0.0002855 | 0.004496 |
60 | REPRESSING TRANSCRIPTION FACTOR BINDING | 4 | 57 | 0.0003931 | 0.006086 |
61 | TRANSCRIPTION COACTIVATOR ACTIVITY | 8 | 296 | 0.0004442 | 0.006766 |
62 | PROTEIN HETERODIMERIZATION ACTIVITY | 10 | 468 | 0.0005588 | 0.00824 |
63 | TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 6 | 168 | 0.0005567 | 0.00824 |
64 | BHLH TRANSCRIPTION FACTOR BINDING | 3 | 28 | 0.0006336 | 0.009197 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | BETA CATENIN DESTRUCTION COMPLEX | 9 | 14 | 1.566e-17 | 9.144e-15 |
2 | WNT SIGNALOSOME | 8 | 11 | 2.306e-16 | 6.735e-14 |
3 | PHOSPHATASE COMPLEX | 11 | 48 | 4.676e-15 | 9.102e-13 |
4 | PROTEIN PHOSPHATASE TYPE 2A COMPLEX | 8 | 20 | 1.683e-13 | 2.457e-11 |
5 | ENDOCYTIC VESICLE MEMBRANE | 14 | 152 | 4.402e-13 | 5.142e-11 |
6 | ENDOCYTIC VESICLE | 15 | 256 | 4.343e-11 | 4.227e-09 |
7 | CATALYTIC COMPLEX | 27 | 1038 | 9.192e-11 | 7.669e-09 |
8 | TRANSCRIPTION FACTOR COMPLEX | 15 | 298 | 3.647e-10 | 2.662e-08 |
9 | PROTEINACEOUS EXTRACELLULAR MATRIX | 16 | 356 | 4.772e-10 | 3.097e-08 |
10 | NUCLEAR CHROMATIN | 14 | 291 | 2.622e-09 | 1.531e-07 |
11 | EXTRACELLULAR MATRIX | 16 | 426 | 6.288e-09 | 3.338e-07 |
12 | CHROMATIN | 16 | 441 | 1.025e-08 | 4.986e-07 |
13 | CHROMOSOME | 22 | 880 | 1.361e-08 | 6.114e-07 |
14 | LATERAL PLASMA MEMBRANE | 7 | 50 | 2.005e-08 | 8.364e-07 |
15 | TRANSCRIPTIONAL REPRESSOR COMPLEX | 7 | 74 | 3.205e-07 | 1.248e-05 |
16 | INTRACELLULAR VESICLE | 24 | 1259 | 4.466e-07 | 1.63e-05 |
17 | VESICLE MEMBRANE | 15 | 512 | 4.848e-07 | 1.666e-05 |
18 | SYNAPSE | 17 | 754 | 2.962e-06 | 9.61e-05 |
19 | NUCLEAR CHROMOSOME | 14 | 523 | 3.435e-06 | 0.0001031 |
20 | CYTOPLASMIC VESICLE PART | 15 | 601 | 3.531e-06 | 0.0001031 |
21 | NUCLEAR TRANSCRIPTION FACTOR COMPLEX | 7 | 127 | 1.222e-05 | 0.0003398 |
22 | GOLGI LUMEN | 6 | 94 | 2.283e-05 | 0.0006061 |
23 | RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX | 6 | 101 | 3.434e-05 | 0.0008719 |
24 | CLATHRIN COATED ENDOCYTIC VESICLE | 5 | 65 | 4.61e-05 | 0.001122 |
25 | SCF UBIQUITIN LIGASE COMPLEX | 4 | 34 | 5.137e-05 | 0.00119 |
26 | CELL SURFACE | 15 | 757 | 5.3e-05 | 0.00119 |
27 | EXCITATORY SYNAPSE | 7 | 197 | 0.0001981 | 0.004211 |
28 | CLATHRIN COATED ENDOCYTIC VESICLE MEMBRANE | 4 | 48 | 0.0002019 | 0.004211 |
29 | PROTEIN KINASE COMPLEX | 5 | 90 | 0.0002175 | 0.004234 |
30 | EXTRACELLULAR SPACE | 20 | 1376 | 0.0002161 | 0.004234 |
31 | TRANSFERASE COMPLEX | 13 | 703 | 0.0003361 | 0.006133 |
32 | SYNAPSE PART | 12 | 610 | 0.0003304 | 0.006133 |
33 | NUCLEAR EUCHROMATIN | 3 | 24 | 0.0003984 | 0.007051 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04310_Wnt_signaling_pathway | 121 | 387 | 4.906e-217 | 8.683e-215 | |
2 | hsa04916_Melanogenesis | 43 | 387 | 6.179e-43 | 5.468e-41 | |
3 | hsa04114_Oocyte_meiosis | 22 | 387 | 1.502e-15 | 8.864e-14 | |
4 | hsa04340_Hedgehog_signaling_pathway | 21 | 387 | 1.771e-14 | 7.837e-13 | |
5 | hsa04010_MAPK_signaling_pathway | 19 | 387 | 2.06e-12 | 7.292e-11 | |
6 | hsa04520_Adherens_junction | 18 | 387 | 2.023e-11 | 5.968e-10 | |
7 | hsa04720_Long.term_potentiation | 16 | 387 | 1.598e-09 | 4.04e-08 | |
8 | hsa04510_Focal_adhesion | 15 | 387 | 1.277e-08 | 2.826e-07 | |
9 | hsa04020_Calcium_signaling_pathway | 14 | 387 | 9.471e-08 | 1.397e-06 | |
10 | hsa04350_TGF.beta_signaling_pathway | 14 | 387 | 9.471e-08 | 1.397e-06 | |
11 | hsa04360_Axon_guidance | 14 | 387 | 9.471e-08 | 1.397e-06 | |
12 | hsa04912_GnRH_signaling_pathway | 14 | 387 | 9.471e-08 | 1.397e-06 | |
13 | hsa04110_Cell_cycle | 13 | 387 | 6.487e-07 | 8.201e-06 | |
14 | hsa04660_T_cell_receptor_signaling_pathway | 13 | 387 | 6.487e-07 | 8.201e-06 | |
15 | hsa04662_B_cell_receptor_signaling_pathway | 12 | 387 | 4.085e-06 | 4.519e-05 | |
16 | hsa04722_Neurotrophin_signaling_pathway | 12 | 387 | 4.085e-06 | 4.519e-05 | |
17 | hsa04012_ErbB_signaling_pathway | 11 | 387 | 2.353e-05 | 0.0001983 | |
18 | hsa04062_Chemokine_signaling_pathway | 11 | 387 | 2.353e-05 | 0.0001983 | |
19 | hsa04370_VEGF_signaling_pathway | 11 | 387 | 2.353e-05 | 0.0001983 | |
20 | hsa04380_Osteoclast_differentiation | 11 | 387 | 2.353e-05 | 0.0001983 | |
21 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 11 | 387 | 2.353e-05 | 0.0001983 | |
22 | hsa04971_Gastric_acid_secretion | 10 | 387 | 0.0001232 | 0.0009914 | |
23 | hsa04270_Vascular_smooth_muscle_contraction | 9 | 387 | 0.0005824 | 0.004296 | |
24 | hsa04530_Tight_junction | 9 | 387 | 0.0005824 | 0.004296 | |
25 | hsa03015_mRNA_surveillance_pathway | 8 | 387 | 0.002464 | 0.01745 | |
26 | hsa04210_Apoptosis | 7 | 387 | 0.009241 | 0.05842 | |
27 | hsa04670_Leukocyte_transendothelial_migration | 7 | 387 | 0.009241 | 0.05842 | |
28 | hsa04730_Long.term_depression | 7 | 387 | 0.009241 | 0.05842 | |
29 | hsa04330_Notch_signaling_pathway | 6 | 387 | 0.03035 | 0.1429 | |
30 | hsa04540_Gap_junction | 6 | 387 | 0.03035 | 0.1429 | |
31 | hsa04620_Toll.like_receptor_signaling_pathway | 6 | 387 | 0.03035 | 0.1429 | |
32 | hsa04630_Jak.STAT_signaling_pathway | 6 | 387 | 0.03035 | 0.1429 | |
33 | hsa04664_Fc_epsilon_RI_signaling_pathway | 6 | 387 | 0.03035 | 0.1429 | |
34 | hsa04810_Regulation_of_actin_cytoskeleton | 6 | 387 | 0.03035 | 0.1429 | |
35 | hsa04910_Insulin_signaling_pathway | 6 | 387 | 0.03035 | 0.1429 | |
36 | hsa04970_Salivary_secretion | 6 | 387 | 0.03035 | 0.1429 | |
37 | hsa04972_Pancreatic_secretion | 6 | 387 | 0.03035 | 0.1429 | |
38 | hsa04740_Olfactory_transduction | 6 | 388 | 0.03068 | 0.1429 | |
39 | hsa04115_p53_signaling_pathway | 5 | 387 | 0.08609 | 0.3544 | |
40 | hsa04120_Ubiquitin_mediated_proteolysis | 5 | 387 | 0.08609 | 0.3544 | |
41 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 5 | 387 | 0.08609 | 0.3544 | |
42 | hsa04710_Circadian_rhythm_._mammal | 5 | 387 | 0.08609 | 0.3544 | |
43 | hsa04914_Progesterone.mediated_oocyte_maturation | 5 | 387 | 0.08609 | 0.3544 | |
44 | hsa04070_Phosphatidylinositol_signaling_system | 4 | 387 | 0.2073 | 0.7978 | |
45 | hsa04621_NOD.like_receptor_signaling_pathway | 4 | 387 | 0.2073 | 0.7978 | |
46 | hsa04622_RIG.I.like_receptor_signaling_pathway | 4 | 387 | 0.2073 | 0.7978 | |
47 | hsa00562_Inositol_phosphate_metabolism | 3 | 387 | 0.416 | 1 | |
48 | hsa03008_Ribosome_biogenesis_in_eukaryotes | 3 | 387 | 0.416 | 1 | |
49 | hsa04144_Endocytosis | 3 | 387 | 0.416 | 1 | |
50 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 3 | 387 | 0.416 | 1 | |
51 | hsa04742_Taste_transduction | 3 | 387 | 0.416 | 1 | |
52 | hsa04920_Adipocytokine_signaling_pathway | 3 | 387 | 0.416 | 1 | |
53 | hsa04962_Vasopressin.regulated_water_reabsorption | 2 | 387 | 0.6824 | 1 | |
54 | hsa04976_Bile_secretion | 2 | 387 | 0.6824 | 1 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | KCNQ1OT1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-143-3p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p;hsa-miR-375 | 12 | CSNK2A1 | Sponge network | 0.459 | 0.00259 | 0.291 | 0.0016 | 0.512 |
2 | KCNQ1OT1 |
hsa-let-7b-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-194-5p;hsa-miR-22-3p;hsa-miR-23b-3p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30c-5p;hsa-miR-30e-3p;hsa-miR-448;hsa-miR-449a | 12 | EP300 | Sponge network | 0.459 | 0.00259 | 0.106 | 0.05719 | 0.504 |
3 | KCNQ1OT1 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30c-5p;hsa-miR-30e-3p;hsa-miR-30e-5p;hsa-miR-373-5p | 15 | SMAD2 | Sponge network | 0.459 | 0.00259 | 0.233 | 0.00027 | 0.502 |
4 | HCG18 |
hsa-miR-125b-5p;hsa-miR-137;hsa-miR-139-5p;hsa-miR-199a-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30c-5p;hsa-miR-373-5p;hsa-miR-448;hsa-miR-449a | 10 | PLCB1 | Sponge network | 0.22 | 0.00721 | 0.803 | 0 | 0.471 |
5 | KTN1-AS1 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30e-3p;hsa-miR-373-5p | 13 | SMAD2 | Sponge network | 0.382 | 0.00019 | 0.233 | 0.00027 | 0.453 |
6 | FAM99A |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-135a-5p;hsa-miR-147a;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-182-3p;hsa-miR-183-5p;hsa-miR-19a-3p;hsa-miR-206;hsa-miR-20a-5p | 11 | CCND1 | Sponge network | -1.52 | 0 | -0.49 | 0.00116 | 0.452 |
7 | HCG18 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30c-5p;hsa-miR-30e-3p;hsa-miR-30e-5p;hsa-miR-373-5p | 15 | SMAD2 | Sponge network | 0.22 | 0.00721 | 0.233 | 0.00027 | 0.448 |
8 | GAS5 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30e-3p;hsa-miR-373-5p | 13 | SMAD2 | Sponge network | 0.239 | 0.00543 | 0.233 | 0.00027 | 0.442 |
9 | HCG18 |
hsa-let-7b-5p;hsa-miR-139-5p;hsa-miR-148a-3p;hsa-miR-194-5p;hsa-miR-22-3p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30c-5p;hsa-miR-30e-3p;hsa-miR-448;hsa-miR-449a | 11 | EP300 | Sponge network | 0.22 | 0.00721 | 0.106 | 0.05719 | 0.411 |
10 | HCG18 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-10b-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-143-3p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p;hsa-miR-375 | 13 | CSNK2A1 | Sponge network | 0.22 | 0.00721 | 0.291 | 0.0016 | 0.398 |
11 | SCARNA15 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-143-3p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p | 11 | CSNK2A1 | Sponge network | 0.373 | 2.0E-5 | 0.291 | 0.0016 | 0.392 |
12 | MIAT |
hsa-let-7a-5p;hsa-let-7d-5p;hsa-let-7f-5p;hsa-miR-105-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-139-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-27b-3p;hsa-miR-378a-5p | 13 | VANGL2 | Sponge network | -0.218 | 0.08268 | -0.357 | 0.11321 | 0.363 |
13 | GAS5 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-10b-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p | 11 | CSNK2A1 | Sponge network | 0.239 | 0.00543 | 0.291 | 0.0016 | 0.334 |
14 | SNHG6 | hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p | 10 | SMAD2 | Sponge network | 0.28 | 0.00038 | 0.233 | 0.00027 | 0.331 |
15 | SNHG8 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-135a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-182-3p;hsa-miR-183-5p;hsa-miR-206;hsa-miR-20a-5p;hsa-miR-34c-5p | 10 | CCND1 | Sponge network | -0.205 | 0.01077 | -0.49 | 0.00116 | 0.318 |
16 | SNHG5 | hsa-miR-148b-3p;hsa-miR-182-5p;hsa-miR-184;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-197-3p;hsa-miR-206;hsa-miR-21-5p;hsa-miR-216a-5p;hsa-miR-330-3p | 10 | PRICKLE2 | Sponge network | -0.338 | 1.0E-5 | -0.71 | 2.0E-5 | 0.31 |
17 | PVT1 | hsa-miR-101-3p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30c-5p;hsa-miR-30e-3p;hsa-miR-30e-5p;hsa-miR-373-5p | 10 | SMAD2 | Sponge network | 0.192 | 0.00873 | 0.233 | 0.00027 | 0.308 |
18 | MIR4435-1HG | hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-30e-3p;hsa-miR-373-5p | 11 | SMAD2 | Sponge network | 0.509 | 0.00035 | 0.233 | 0.00027 | 0.296 |
19 | MEG3 |
hsa-let-7a-5p;hsa-let-7d-5p;hsa-miR-105-5p;hsa-miR-139-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-196a-5p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-30a-5p;hsa-miR-378a-5p | 11 | VANGL2 | Sponge network | 0 | 0.99719 | -0.357 | 0.11321 | 0.284 |
20 | KTN1-AS1 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-143-3p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p | 11 | CSNK2A1 | Sponge network | 0.382 | 0.00019 | 0.291 | 0.0016 | 0.281 |
21 | SCARNA15 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30e-3p;hsa-miR-373-5p | 11 | SMAD2 | Sponge network | 0.373 | 2.0E-5 | 0.233 | 0.00027 | 0.28 |
22 | SNHG3 |
hsa-let-7a-5p;hsa-miR-101-3p;hsa-miR-144-3p;hsa-miR-145-5p;hsa-miR-148a-3p;hsa-miR-152-3p;hsa-miR-192-5p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-30a-3p;hsa-miR-373-5p | 11 | SMAD2 | Sponge network | 0.394 | 0.00858 | 0.233 | 0.00027 | 0.272 |
23 | HCG18 |
hsa-miR-10a-5p;hsa-miR-126-5p;hsa-miR-137;hsa-miR-139-5p;hsa-miR-143-3p;hsa-miR-30a-3p;hsa-miR-30e-3p;hsa-miR-373-5p;hsa-miR-375;hsa-miR-448 | 10 | MAP3K7 | Sponge network | 0.22 | 0.00721 | 0.198 | 0.01129 | 0.262 |
24 | MEG3 |
hsa-miR-105-5p;hsa-miR-148b-3p;hsa-miR-152-3p;hsa-miR-182-5p;hsa-miR-184;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-197-3p;hsa-miR-206;hsa-miR-216a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-330-3p;hsa-miR-346 | 15 | PRICKLE2 | Sponge network | 0 | 0.99719 | -0.71 | 2.0E-5 | 0.255 |
25 | SNHG3 |
hsa-let-7a-5p;hsa-let-7b-5p;hsa-let-7c-5p;hsa-miR-10a-5p;hsa-miR-125a-5p;hsa-miR-125b-5p;hsa-miR-22-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-373-5p | 10 | CSNK2A1 | Sponge network | 0.394 | 0.00858 | 0.291 | 0.0016 | 0.251 |